US20130190239A1 - Formulations Comprising Linaclotide - Google Patents
Formulations Comprising Linaclotide Download PDFInfo
- Publication number
- US20130190239A1 US20130190239A1 US13/840,821 US201313840821A US2013190239A1 US 20130190239 A1 US20130190239 A1 US 20130190239A1 US 201313840821 A US201313840821 A US 201313840821A US 2013190239 A1 US2013190239 A1 US 2013190239A1
- Authority
- US
- United States
- Prior art keywords
- linaclotide
- composition
- composition comprises
- weight
- cation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 729
- 229960000812 linaclotide Drugs 0.000 title claims abstract description 615
- 108010024409 linaclotide Proteins 0.000 title claims abstract description 615
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 title claims abstract description 613
- 238000009472 formulation Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 39
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 120
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 120
- 229960003136 leucine Drugs 0.000 claims description 120
- 150000001768 cations Chemical class 0.000 claims description 113
- 230000000087 stabilizing effect Effects 0.000 claims description 113
- -1 hydroxylpropyl Chemical group 0.000 claims description 85
- 150000003141 primary amines Chemical class 0.000 claims description 69
- 238000004519 manufacturing process Methods 0.000 claims description 61
- 229920000642 polymer Polymers 0.000 claims description 55
- 150000003839 salts Chemical class 0.000 claims description 51
- 230000003647 oxidation Effects 0.000 claims description 49
- 238000007254 oxidation reaction Methods 0.000 claims description 49
- 230000007062 hydrolysis Effects 0.000 claims description 44
- 238000006460 hydrolysis reaction Methods 0.000 claims description 44
- 229940024606 amino acid Drugs 0.000 claims description 43
- 235000001014 amino acid Nutrition 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 40
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 40
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 39
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 37
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 37
- 229910052751 metal Inorganic materials 0.000 claims description 33
- 239000002184 metal Substances 0.000 claims description 33
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 26
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 26
- 229960000310 isoleucine Drugs 0.000 claims description 26
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 25
- 229960003767 alanine Drugs 0.000 claims description 25
- 235000004279 alanine Nutrition 0.000 claims description 25
- 239000007853 buffer solution Substances 0.000 claims description 24
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 23
- 229930182817 methionine Natural products 0.000 claims description 23
- 229960004452 methionine Drugs 0.000 claims description 23
- 206010010774 Constipation Diseases 0.000 claims description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 15
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 14
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 14
- 229960002433 cysteine Drugs 0.000 claims description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 14
- 235000018417 cysteine Nutrition 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 14
- 229960002429 proline Drugs 0.000 claims description 14
- 229960001153 serine Drugs 0.000 claims description 14
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 13
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 229960003121 arginine Drugs 0.000 claims description 11
- 235000009697 arginine Nutrition 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 229960002885 histidine Drugs 0.000 claims description 11
- 235000018977 lysine Nutrition 0.000 claims description 11
- 229960003646 lysine Drugs 0.000 claims description 11
- 229960004441 tyrosine Drugs 0.000 claims description 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
- 239000004473 Threonine Substances 0.000 claims description 10
- 229960001230 asparagine Drugs 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- 201000006549 dyspepsia Diseases 0.000 claims description 10
- 229960002989 glutamic acid Drugs 0.000 claims description 10
- 235000013922 glutamic acid Nutrition 0.000 claims description 10
- 239000004220 glutamic acid Substances 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 229960002743 glutamine Drugs 0.000 claims description 10
- 235000004554 glutamine Nutrition 0.000 claims description 10
- 229960002449 glycine Drugs 0.000 claims description 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 10
- 229960002898 threonine Drugs 0.000 claims description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001983 poloxamer Polymers 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 229920001661 Chitosan Polymers 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 229960004295 valine Drugs 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 229960005261 aspartic acid Drugs 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 239000011575 calcium Substances 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 235000010981 methylcellulose Nutrition 0.000 claims description 7
- 239000001923 methylcellulose Substances 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- 229960005190 phenylalanine Drugs 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 229920000744 poly(arginines) Polymers 0.000 claims description 6
- 239000004584 polyacrylic acid Substances 0.000 claims description 6
- 229950005134 polycarbophil Drugs 0.000 claims description 6
- 229920000573 polyethylene Polymers 0.000 claims description 6
- 229920001451 polypropylene glycol Polymers 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052782 aluminium Inorganic materials 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 235000010417 guar gum Nutrition 0.000 claims description 5
- 239000000665 guar gum Substances 0.000 claims description 5
- 229960002154 guar gum Drugs 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 229940071745 poly(sodium vinyl sulfonate) Drugs 0.000 claims description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 229960004799 tryptophan Drugs 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 4
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229910052788 barium Inorganic materials 0.000 claims description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- 239000011651 chromium Substances 0.000 claims description 4
- 239000010941 cobalt Substances 0.000 claims description 4
- 229910017052 cobalt Inorganic materials 0.000 claims description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 229910052759 nickel Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229910052718 tin Inorganic materials 0.000 claims description 3
- 239000011135 tin Substances 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000005078 Colonic Pseudo-Obstruction Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 claims description 2
- 206010054048 Postoperative ileus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 claims description 2
- 208000001288 gastroparesis Diseases 0.000 claims description 2
- 150000002337 glycosamines Chemical class 0.000 claims description 2
- 208000024798 heartburn Diseases 0.000 claims description 2
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 claims description 2
- 230000002981 neuropathic effect Effects 0.000 claims description 2
- 229940026510 theanine Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 7
- 239000000047 product Substances 0.000 description 164
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 136
- 239000003826 tablet Substances 0.000 description 134
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 116
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 91
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 86
- 239000012728 immediate-release (IR) tablet Substances 0.000 description 75
- 229910052623 talc Inorganic materials 0.000 description 70
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 69
- 229960000913 crospovidone Drugs 0.000 description 69
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 69
- 239000000905 isomalt Substances 0.000 description 69
- 235000010439 isomalt Nutrition 0.000 description 69
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 69
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 69
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 69
- 239000000454 talc Substances 0.000 description 69
- 235000012222 talc Nutrition 0.000 description 69
- 235000019359 magnesium stearate Nutrition 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- 229920000881 Modified starch Polymers 0.000 description 56
- 239000003381 stabilizer Substances 0.000 description 45
- 229920003081 Povidone K 30 Polymers 0.000 description 44
- 239000000243 solution Substances 0.000 description 44
- 239000000945 filler Substances 0.000 description 41
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 36
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 36
- 230000021736 acetylation Effects 0.000 description 33
- 238000006640 acetylation reaction Methods 0.000 description 33
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 33
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 32
- 239000001110 calcium chloride Substances 0.000 description 32
- 229910001628 calcium chloride Inorganic materials 0.000 description 32
- 235000011148 calcium chloride Nutrition 0.000 description 32
- 229960002713 calcium chloride Drugs 0.000 description 31
- 239000000654 additive Substances 0.000 description 29
- 238000004090 dissolution Methods 0.000 description 21
- 239000008380 degradant Substances 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 238000000576 coating method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 12
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 11
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 9
- 239000002274 desiccant Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000007884 disintegrant Substances 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 7
- 229960001681 croscarmellose sodium Drugs 0.000 description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 7
- 150000004683 dihydrates Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 229940014259 gelatin Drugs 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000007916 tablet composition Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 5
- 229940038472 dicalcium phosphate Drugs 0.000 description 5
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 5
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical group SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 125000002228 disulfide group Chemical group 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000011147 magnesium chloride Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 150000002892 organic cations Chemical class 0.000 description 3
- 239000006179 pH buffering agent Substances 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- 235000001508 sulfur Nutrition 0.000 description 3
- 229940074410 trehalose Drugs 0.000 description 3
- 239000004246 zinc acetate Substances 0.000 description 3
- 235000013904 zinc acetate Nutrition 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ISWAQPWFWKGCAL-ACZMJKKPSA-N Cys-Cys-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISWAQPWFWKGCAL-ACZMJKKPSA-N 0.000 description 2
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 108010069495 cysteinyltyrosine Proteins 0.000 description 2
- 230000006240 deamidation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008991 intestinal motility Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 2
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- SLPUVFBNQHVEEU-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid;2-oxopentanedioic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CCC(=O)C(O)=O SLPUVFBNQHVEEU-WCCKRBBISA-N 0.000 description 1
- PGRNZHOQVAPMFX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N PGRNZHOQVAPMFX-WCCKRBBISA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- AKGWUHIOEVNNPC-LURJTMIESA-N Arg-OEt Chemical compound CCOC(=O)[C@@H](N)CCCNC(N)=N AKGWUHIOEVNNPC-LURJTMIESA-N 0.000 description 1
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 229930028154 D-arginine Natural products 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FOUZISDNESEYLX-UHFFFAOYSA-N N-hydroxyethyl glycine Natural products OCCNCC(O)=O FOUZISDNESEYLX-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- CMWRPTYOFZMJLC-UHFFFAOYSA-N acetic acid;n,n'-bis(3-aminopropyl)butane-1,4-diamine Chemical compound CC(O)=O.NCCCNCCCCNCCCN CMWRPTYOFZMJLC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940075858 ornithine alpha-ketoglutarate Drugs 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Definitions
- the present invention relates to stable formulations comprising linaclotide, processes for making the compositions and methods of treating conditions using the compositions.
- U.S. Pat. Nos. 7,304,036 and 7,371,727 disclose peptides that act as agonists of the guanylate cyclase C (GC-C) receptor for the treatment of gastrointestinal disorders.
- GC-C guanylate cyclase C
- One particular peptide disclosed is linaclotide, which consists of the following amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 1).
- the '036 and '727 patents also disclose methods for preparing linaclotide and related peptides. The contents of these patents are incorporated herein by reference in their entirety.
- the present invention seeks to provide such improved formulations of linaclotide, as well as processes for making the formulations and methods of treating gastrointestinal disorders by administering the formulations.
- a stable pharmaceutical composition comprising linaclotide and a pharmaceutically acceptable carrier is provided.
- a pharmaceutical composition of linaclotide comprises a stabilizing amount of a polymer, a stabilizing amount of a sterically hindered primary amine, a stabilizing amount of a cation, or a combination or mixture thereof.
- an immediate release pharmaceutical composition comprising linaclotide, or a pharmaceutically acceptable salt thereof is provided.
- a method of treating a gastrointestinal disorder comprising administering to a patient in need thereof, a therapeutically effective amount of the compositions is provided.
- Stable formulations of linaclotide are provided herein.
- methods of using the formulations to treat gastrointestinal disorders including irritable bowel syndrome (“IBS”) (for example, constipation-predominant IBS) and/or constipation (for example, chronic constipation), and processes for making the compositions are provided.
- IBS irritable bowel syndrome
- constipation-predominant IBS constipation-predominant IBS
- constipation for example, chronic constipation
- the stability of linaclotide compositions can be increased or improved by including in the compositions a suitable amount of a polymer component, a sterically hindered primary amine (e.g., amino acid) component, and/or a cation (e.g., metal cation) component.
- a polymer component e.g., polyethylene glycol
- a sterically hindered primary amine e.g., amino acid
- a cation e.g., metal cation
- addition or inclusion of a suitable amount of a cation (e.g. Mg 2+ , Ca 2+ , Zn 2+ ) in the composition increases the stability of the composition against oxidative degradation of linaclotide.
- inclusion of a suitable amount of a sterically hindered primary amine (e.g., leucine) in the composition increases the stability of the composition against the formation of formaldehyde imine adducts of linaclotide.
- inclusion of both a sterically hindered primary amine (e.g. leucine) and a cation (e.g. Ca 2+ ) in suitable amounts in the composition increases the stability of the composition against the formation of hydrolysis products of linaclotide.
- inclusion of a suitable amount of a polymer (e.g. polyvinyl pyrrolidone or polyvinyl alcohol) in the composition increases the stability of the composition for example by decreasing the mobility and/or reactivity of linaclotide within the composition. e.g., by forming a complex or matrix (for example, a glassy and/or rigid matrix) with linaclotide (e.g., by vitrification reaction), by preventing or lessening hydrogen bond formation between linaclotide and water molecules, and/or by enhancing the three-dimensional structural integrity of linaclotide.
- a polymer e.g. polyvinyl pyrrolidone or polyvinyl alcohol
- combining linaclotide with specific amounts or ratios of polymer, sterically hindered primary amine and cation causes a synergistic enhancement or improvement in the stability of linaclotide within pharmaceutical compositions, for example as compared to pharmaceutical compositions not containing the polymer, sterically hindered primary amine and cation and/or the same concentrations of these components.
- Suitable polymers for inclusion in the composition are, for example, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxylpropyl methyl cellulose (tHPMC), hydroxylpropyl cellulose (HPC), methyl cellulose, methacrylate polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, guar gum, xanthan gum, polyethylene polypropylene oxide, poly(sodium vinylsulfonate), polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer (e.g., PLURONIC® products available from BASF), or a combination or mixture thereof.
- PVP polyvinyl pyrrolidone
- PVA polyvinyl alcohol
- tHPMC hydroxylpropyl methyl cellulose
- HPC hydroxylpropyl cellulose
- the composition comprises a polymer selected from PVP, PVA, methacrylate polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, guar gum, xanthan gum, polyethylene polypropylene oxide, polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer, or a combination or mixture thereof.
- the composition comprises PVP, PVA, or a mixture thereof.
- the composition comprises PVP.
- the composition comprises PVA.
- the composition comprises methacrylate polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, xanthan gum, polyethylene polypropylene oxide, poly(sodium vinylsulfonate), polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer (e.g. PLURONIC® products available from BASF), or a combination or mixture thereof.
- methacrylate polymers cyclodextrin, dextran, polyacrylic acid, chitosan, xanthan gum, polyethylene polypropylene oxide, poly(sodium vinylsulfonate), polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer (e.g. PLURONIC® products available from BASF), or a combination or mixture thereof.
- PLURONIC® products
- the composition can contain any stabilizing amount of a polymer.
- the composition comprises between 0.01 and 10 wt. % of a polymer. In some embodiments, the composition comprises between 2.5 and 10 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 5 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 4 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 3 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 2.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of a polymer.
- the composition comprises between 0.5 and 2.5 wt. % of a polymer. In some embodiments, the composition comprises between 1 and 2.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.01% and 2 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 2 wt. % of a polymer. In some embodiments, the composition comprises between 0.5 and 2 wt. % of a polymer. In some embodiments, the composition comprises between 1 and 2 wt. % of a polymer.
- the composition comprises between 0.01 and 1.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 1.25 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 1 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 1 wt. % of a polymer. In some embodiments, the composition comprises between 0.5 and 1 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 0.5 wt. % of a polymer.
- Suitable sterically hindered primary amines for inclusion in the composition are, for example, naturally-occurring amino acids (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine), synthetic amino acids (e.g., lanthionine, theanine or 1-amino cyclohexane), amino sugars (e.g., chitosan or glucosamine), or combination or mixtures thereof.
- amino acids e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine,
- the composition comprises an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof.
- the composition comprises an amino acid selected from leucine, isoleucine, asparagine, glutamine, glutamic acid, histidine, cysteine, alanine, serine, threonine, tyrosine, proline, tryptophan, or a combination or mixture thereof.
- the composition comprises an amino acid selected from leucine, isoleucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, methionine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises leucine, methionine, or a mixture thereof.
- the composition comprises leucine, isoleucine, or a mixture thereof. In some embodiments, the composition comprises leucine, alanine, or a mixture thereof. In some embodiments, the composition comprises leucine. In some embodiments, the composition comprises isoleucine. In some embodiments, the composition comprises methionine. In some embodiments, the composition comprises alanine. In some embodiments, the composition comprises an amino acid selected from arginine, cysteine, glycine, lysine, proline, serine, or a mixture thereof. In some embodiments, the composition comprises 1-amino cyclohexane.
- the composition can comprise any stabilizing amount of a sterically hindered primary amine component.
- the composition can comprise a molar ratio of sterically hindered primary amine (e.g., amino acid) to linaclotide between 100:1 and 1:100.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 1:1.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 90:1 and 2:1.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 80:1 and 5:1.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 70:1 and 10:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 60:1 and 20:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 50:1 and 30:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 40:1 and 20:1.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 20:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 25:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 30:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 50:1.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 60:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 70:1.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 5:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 10:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 20:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 25:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 30:1.
- the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 40:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 5:1 and 1:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 1:100 and 1:1.
- the composition comprises about 0.5 to about 10% by weight of a sterically hindered primary amine relative to the total weight of the pharmaceutical composition (e.g., solid oral dosage form or bead). In some embodiments, the composition comprises about 0.5 to about 7% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.5 to about 5% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.5 to about 4% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.5 to about 3% by weight of a sterically hindered primary amine.
- the composition comprises about 0.5 to about 2% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 5% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 4% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 3% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 2% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 1 to about 5% by weight of a sterically hindered primary amine.
- the composition comprises about 1 to about 4% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 1 to about 3% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 1 to about 2% by weight of a sterically hindered primary amine.
- the composition comprises a metal cation selected from calcium, potassium, magnesium, zinc, aluminum, iron, tin, manganese, chromium, cobalt, nickel, barium, sodium, or a combination or mixture thereof.
- the composition comprises a metal cation selected from iron, tin, chromium, cobalt, nickel, barium, or a combination or mixture thereof.
- the composition comprises a metal cation selected from calcium, potassium, magnesium, zinc, aluminum, manganese, chromium, cobalt, nickel, barium, sodium, or a combination or mixture thereof.
- the composition comprises a metal cation selected from aluminum, calcium, potassium, sodium, magnesium, manganese, zinc, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from calcium, magnesium, manganese, zinc, or a combination or mixture thereof. In some embodiments, the composition comprises a divalent metal cation. In some embodiments, the composition comprises a divalent metal cation selected from Ca 2+ , Mg 2+ , Zn 2+ , Mn 2+ , or a combination or mixture thereof. In some embodiments, the composition comprises Mg 2+ . In some embodiments, the composition comprises Ca 2+ . In some embodiments, the composition comprises Zn 2+ . In some embodiments, the composition comprises aluminum.
- the metal cation can be added to the composition in any suitable form, for example any pharmaceutically acceptable salt with any appropriate counterion.
- Suitable metal salts include, for example, calcium chloride, calcium carbonate, calcium acetate, magnesium chloride, magnesium acetate, zinc acetate, zinc chloride, or mixtures thereof.
- the composition comprises calcium chloride, magnesium chloride, zinc acetate, or any combination or mixture thereof.
- the composition comprises calcium chloride.
- the composition comprises magnesium chloride.
- the composition comprises zinc acetate.
- Suitable organic cations include, for example, ammonium hydroxide.
- L-serine sodium hydroxide, DL-triptophan, tromethamine, L-tyrosine, L-valine, carnitine, taurine, creatine malate, arginine alpha keto glutarate, ornithine alpha keto glutarate, spermine acetate, spermidine chloride, or combinations or mixtures thereof.
- the organic cation is selected from the group consisting of N-methyl D-glucamine, choline, arginine, lysine, procaine, tromethamine (TRIS), spermine, N-methyl-morpholine, glucosamine, N,N-bis 2-hydroxyethyl glycine, diazabicycloundecene, creatine, arginine ethyl ester, amantadine, rimantadine, ornithine, taurine, citrulline, or a combination or mixture thereof.
- TMS tromethamine
- the composition can comprise any stabilizing amount of a cation.
- the composition can comprise a molar ratio of cation to linaclotide between 100:1 and 1:100.
- the composition comprises a molar ratio of cation to linaclotide between 100:1 and 1:1.
- the composition comprises a molar ratio of cation to linaclotide between 90:1 and 2:1.
- the composition comprises a molar ratio of cation to linaclotide between 80:1 and 5:1.
- the composition comprises a molar ratio of cation to linaclotide between 70:1 and 10:1.
- the composition comprises a molar ratio of cation to linaclotide between 60:1 and 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 50:1 and 30:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 40:1 and 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 25:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 30:1.
- the composition comprises a molar ratio of cation to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 50:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 60:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 70:1.
- the composition comprises a molar ratio of cation to linaclotide of at least 5:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 10:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 25:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 30:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 40:1.
- the composition comprises a molar ratio of cation to linaclotide of at least 60:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 5:1 and 1:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 1:100 and 1:1.
- the composition comprises about 0.5 to about 5% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 4% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 2% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 1.5% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 1.25% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 1% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.6 to about 1.5% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.6 to about 1.25% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.6 to about 1% by weight of the cation or salt thereof.
- the composition comprises two or more stabilizing agents.
- the composition can include a stabilizing amount of a polymer and a stabilizing amount of a sterically hindered primary amine.
- the composition can include a stabilizing amount of a polymer and a stabilizing amount of a cation (e.g., metal cation).
- the composition can include a stabilizing amount of a sterically hindered primary amine and a stabilizing amount of a cation (e.g., metal cation).
- the composition comprises a stabilizing amount of a polymer, a stabilizing amount of a sterically hindered primary amine, and a stabilizing amount of a cation.
- the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVP and a stabilizing amount (e.g. a molar ratio of amino acid to linaclotide between 100:1 and 30:1 or between 60:1 and 30:1) of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof.
- a stabilizing amount e.g., about 0.1-2.5 wt. % of PVP and a stabilizing amount (e.g. a molar ratio of amino acid to linaclotide between 100:1 and 30:1 or between 60:1 and 30:1) of an amino acid selected from
- the composition comprises a stabilizing amount of PVP and a stabilizing amount of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof.
- the composition comprises a stabilizing amount of PVP and a stabilizing amount of leucine, isoleucine, methionine, alanine, or a combination or mixture thereof.
- the composition comprises a stabilizing amount of PVP and a stabilizing amount of leucine. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of arginine, cysteine, glycine, lysine, proline, serine, or a mixture thereof.
- the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVA and a stabilizing amount (e.g., a molar ratio of amino acid to linaclotide between 100:1 and 30:1 or between 60:1 and 30:1) of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof.
- a stabilizing amount e.g., about 0.1-2.5 wt. % of PVA and a stabilizing amount (e.g., a molar ratio of amino acid to linaclotide between 100:1 and 30:1 or between 60:1 and 30:1) of an amino acid selected
- the composition comprises a stabilizing amount of PVA and a stabilizing amount of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof.
- the composition comprises a stabilizing amount of PVA and a stabilizing amount of leucine, isoleucine, methionine, alanine, or a combination or mixture thereof.
- the composition comprises a stabilizing amount of PVA and a stabilizing amount of leucine. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of arginine, cysteine, glycine, lysine, proline, serine, or a mixture thereof.
- the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVP and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- the composition comprises a stabilizing amount of PVP and a stabilizing amount of a divalent metal cation.
- the composition comprises a stabilizing amount of PVP and a stabilizing amount of Mg 2+ , Ca 2+ , Zn 2+ or a salt thereof or a combination or mixture thereof.
- the composition comprises a stabilizing amount of PVP and a stabilizing amount of Ca 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Mg 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Zn 2+ or a salt thereof.
- the composition comprises a stabilizing amount (e.g., about 0.1-0.5 wt. %) of PVP and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- a stabilizing amount e.g., about 0.1-0.5 wt. %) of PVP and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVA and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- a stabilizing amount of PVA and a stabilizing amount of a divalent metal cation e.g., the composition comprises a stabilizing amount of PVA and a stabilizing amount of Mg 2+ , Ca 2+ , Zn 2+ or a salt thereof or a combination or mixture thereof.
- the composition comprises a stabilizing amount of PVA and a stabilizing amount of Ca 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Mg 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Zn 2+ or a salt thereof.
- the composition comprises a stabilizing amount (e.g., about 0.1-0.5 wt. %) of PVA and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- a stabilizing amount e.g., about 0.1-0.5 wt. %) of PVA and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- the composition comprises a stabilizing amount (e.g., a molar ratio of amino acid to linaclotide between 100:1 and 30:1, between 60:1 and 30:1, or even between 50:1 and 30:1) of an amino acid selected from leucine, isoleucine, methionine, alanine; and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a divalent metal cation selected from Mg 2+ , Ca 2+ , Zn 2+ or a salt thereof or a combination or mixture thereof.
- a stabilizing amount e.g., a molar ratio of amino acid to linaclotide between 100:1 and 30:1, between 60:1 and 30:1, or even between 50:1 and 30:1
- an amino acid selected from leucine, isoleucine, methionine, alanine e.g., a
- the composition comprises a stabilizing amount of an amino acid selected from leucine, isoleucine; and a stabilizing amount of a divalent metal cation selected from Mg 2+ , Ca 2+ or a salt thereof or a combination or mixture thereof.
- the composition comprises a stabilizing amount of an amino acid selected from leucine or methionine; and a stabilizing amount of a divalent metal cation selected from Ca 2+ , Zn 2+ or a salt thereof or a combination or mixture thereof.
- the composition comprises a stabilizing amount of leucine and a stabilizing amount of Ca 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of a cation and a stabilizing amount of a sterically hindered primary amine.
- the composition comprises a cation and a sterically hindered primary amine in a molar ratio of cation:sterically hindered primary amine (e.g., Ca 2+ :leucine) of at least 1.5:1, e.g., at least 2:1, at least 2.5:1, at least 3:1, at least 4:1, or even at least 5:1 (for example, a molar ratio between 1.5:1 and 5:1, e.g., between 2:1 and 4:1, and between 1.5:1 and 2:1).
- a molar ratio between 1.5:1 and 5:1, e.g., between 2:1 and 4:1, and between 1.5:1 and 2:1 for example, a molar ratio between 1.5:1 and 5:1, e.g., between 2:1 and 4:1, and between 1.5:1 and 2:1.
- the composition comprises (i) a stabilizing amount of PVP or PVA, (ii) a stabilizing amount of leucine, isoleucine, methionine, alanine, and (iii) a stabilizing amount of Mg 2+ , Ca 2+ , Zn 2+ or a salt thereof or a combination or mixture thereof.
- the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of a metal cation.
- the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Ca 2+ or a salt thereof.
- the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Mg 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Zn 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Ca 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Mg 2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Zn 2+ or a salt thereof.
- the composition comprises (i) between 0.01 and 5 wt. % of a polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide between 100:1 and 10:1, and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide between 100:1 and 40:1.
- the composition comprises (i) between 0.1 and 3 wt.
- a polymer e.g., a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide 100:1 and 30:1 (e.g., between 60:1 and 30:1 or even between 50:1 and 30:1), and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide between 100:1 and 60:1.
- a sterically hindered primary amine e.g., an amino acid
- a cation e.g., a metal cation
- the composition comprises (i) between 0.01 and 5 wt. % of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide between 100:1 and 10:1, and (iii) a metal cation selected from Ca 2+ , Mg 2+ , and Zn 2+ in a molar ratio of cation to linaclotide between 100:1 and 40:1.
- the composition comprises (i) between 0.1 and 3 wt. % of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide 100:1 and 30:1 (e.g., between 60:1 and 30:1), and (iii) a metal cation selected from Ca 2+ , Mg 2+ , and Zn 2+ in a molar ratio of cation to linaclotide between 100:1 and 60:1.
- the composition comprises (i) between 0.01 and 5 wt.
- % (e.g., between 0.1 and 3 wt. % or even between 0.1 and 2.5 wt. %) of PVP or PVA, (ii) leucine in a molar ratio of leucine to linaclotide between 100:1 and 30:1 (e.g., between 60:1 and 30:1 or even between 50:1 and 30:1), and (iii) Ca 2+ in a molar ratio of Ca 2+ to linaclotide between 100:1 and 60:1.
- the composition comprises (i) between 0.01 and 5 wt. % (e.g., between 0.1 and 3 wt. % or even between 0.1 and 2.5 wt. %) of PVP, PVA or HPMC, (ii) leucine in a molar ratio of leucine to linaclotide between 60:1 and 10:1 (e.g., between 50:1 and 10:1 or even between 40:1 and 20:1), and (iii) Ca 2+ (or salt thereof) in a molar ratio of Ca 2+ (or salt thereof) to linaclotide between 100:1 and 40:1 (e.g., between 80:1 and 40:1 or between 70:1 and 50:1).
- the composition comprises (i) between 0.01 and 5 wt. % (e.g., between 0.1 and 3 wt. % or even between 0.1 and 2.5 wt. %) of HPMC, (ii) leucine in a molar ratio of leucine to linaclotide between 60:1 and 10:1 (e.g., between 50:1 and 10:1 or even between 40:1 and 20:1), and (iii) Ca 2+ (or salt thereof) in a molar ratio of Ca 2+ (or salt thereof) to linaclotide between 100:1 and 40:1 (e.g., between 80:1 and 40:1 or between 70:1 and 50:1).
- leucine in a molar ratio of leucine to linaclotide between 60:1 and 10:1 (e.g., between 50:1 and 10:1 or even between 40:1 and 20:1)
- the composition comprises (i) between 0.01 and 0.5 wt. % of a polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide between 100:1 and 10:1, and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide between 100:1 and 40:1.
- the composition comprises (i) between 0.01 and 5 wt.
- the composition comprises (i) between 0.01 and 0.5 wt.
- the composition comprises (i) between 0.01 and 5 wt.
- % of a polymer selected from PVP and PVA (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide between 100:1 and 50:1, and (iii) a metal cation selected from Ca 2+ , Mg 2+ , and Zn 2+ in a molar ratio of cation to linaclotide between 100:1 and 40:1.
- the composition comprises linaclotide (e.g., between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide), Ca 2+ or a salt thereof in a concentration between 1.2 and 1.8% by weight, leucine in a concentration between 0.5 and 0.9% by weight, and optionally between 0.5 and 0.9% by weight (e.g., between 0.6 and 0.75% by weight) of HPMC.
- linaclotide e.g., between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide
- Ca 2+ or a salt thereof in a concentration between 1.2 and 1.8% by weight
- leucine in a concentration between 0.5 and 0.9% by weight
- optionally between 0.5 and 0.9% by weight e.g., between 0.6 and 0.75% by weight
- the composition comprises linaclotide (e.g., between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide), Ca 2+ or a salt thereof in a concentration between 1.4 and 1.65% by weight, leucine in a concentration between 0.5 and 0.8% by weight, and optionally between 0.5 and 0.9% by weight (e.g., between 0.6 and 0.75% by weight) of HPMC.
- the composition comprises linaclotide (e.g., between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide), Ca 2+ or a salt thereof in a concentration between 1.4 and 1.65% by weight, leucine in a concentration between 0.5 and 0.8% by weight, and optionally between 0.5 and 0.9% by weight (e.g., between 0.6 and 0.75% by weight) of HPMC.
- the composition comprises linaclotide (e.g.
- linaclotide between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide), Ca or a salt thereof in a concentration between 1.45 and 1.65% by weight, leucine in a concentration between 0.6 and 0.75% by weight, and optionally between 0.5 and 0.9% by weight (e.g., between 0.6 and 0.75% by weight) of HPMC.
- the pharmaceutical composition comprises linaclotide, leucine in a molar ratio of leucine to linaclotide between 70:1 and 10:1 and Ca 2+ or a salt thereof in a molar ratio of Ca 2+ or a salt thereof to linaclotide between 100:1 and 30:1.
- the composition comprises a molar ratio of Ca 2+ or a salt thereof to linaclotide between 100:1 and 40:1.
- the composition comprises a molar ratio of leucine to linaclotide between 60:1 and 20:1 and a molar ratio of Ca 2+ or a salt thereof to linaclotide between 100:1 and 40:1.
- the composition comprises a molar ratio of leucine to linaclotide between 40:1 and 20:1. In some embodiments, the composition comprises a molar ratio of leucine to linaclotide between 40:1 and 20:1. In some embodiments, the composition comprises a molar ratio of Ca 2+ or a salt thereof to leucine between 1.5:1 and 5:1. In still further embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering a use environment.
- the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering a use environment. In some further embodiments, the composition comprises between 100 ⁇ g and 300 ⁇ g of linaclotide. In some embodiments, the composition comprises about 266 ⁇ g of linaclotide. In some embodiments, the composition comprises about 133 ⁇ g of linaclotide. In some embodiments, the composition further comprises hydroxypropyl methyl cellulose. In some embodiments, the composition is a capsule. In some embodiments, the composition is a tablet.
- the pharmaceutical composition comprises linaclotide, leucine in a molar ratio of leucine to linaclotide between 70:1 and 10:1, and Ca 2+ or a salt thereof in a molar ratio of Ca 2+ or a salt thereof to leucine between 1.5:1 and 5:1.
- the composition comprises leucine in a molar ratio to linaclotide between 50:1 and 10:1.
- the composition comprises leucine in molar ratio to linaclotide between 40:1 and 20:1.
- the composition may also comprise any suitable pharmaceutically acceptable carrier or medium.
- suitable pharmaceutically acceptable carriers include, for example, any solvents, dispersants, pH buffering agents, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients (e.g., filling agents, starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents), or the like.
- the compositions can contain any desired additional components, additives, and/or species, for example, surface active additives, dispersing additives, humectants, suspending agents, solubilizers, buffering agents, disintegrants, preservatives, colorants, flavorants, and the like.
- the composition comprises one or more ion species that interact with linaclotide.
- the composition can also comprise any suitable pH buffering agent.
- the pH buffering agent is present in the composition in an amount sufficient to achieve the isoelectric point of linaclotide.
- the composition can have any desired pH.
- the composition has a pH of 2 to 5 (for example, a pH of 2 to 4.5, a pH of 2 to 4, a pH of 2.5 to 4, a pH of 2.5 to 3.5, a pH1 of 2.5 to 3, or even a pH of 3).
- the composition may also comprise any one or more filling agents.
- suitable filling agents include, but are not limited to starch, calcium carbonate, calcium sulfate, hydroxylpropylmethyl cellulose, fructose, methyl cellulose, dextrates, dextrose, lactitol, maltose, sucrose, sorbitol, isomalt, pregelatinized starch, dicalcium phosphate, microcrystalline cellulose, mannitol, gelatin, trehalose, erythitol, maltitol, lactose, glucose, or a combination thereof, or a mixture thereof.
- the filling agent is isomalt.
- the filling agent is gelatin.
- the tilling agent is mannitol. In some embodiments, the filling agent is pregelatinized starch. In some embodiments, the filling agent is microcrystalline cellulose. In some embodiments, the composition comprises a tablet filler and a granule filler.
- the composition can comprise any suitable concentration of filling agent.
- the composition comprises one or more filling agents in a concentration of 0.1-95% by weight, relative to the total weight of the composition.
- the composition comprises one or more filling agents in a concentration of 1-90 wt. % of filling agent(s), relative to the total weight of the composition.
- the composition comprises one or more filling agents in a concentration of 10-90 wt. % of filling agent(s), relative to the total weight of the composition.
- the composition comprises one or more filling agents in a concentration of 20-90 wt. % of filling agent(s), relative to the total weight of the composition.
- the composition comprises one or more filling agents in a concentration of 30-80 wt. % of filling agent(s), relative to the total weight of the composition, in some embodiments, the composition comprises one or more filling agents in a concentration of at least wt. %, for example, at least 40 wt. %, at least 60 wt. %, or at least 80 wt. %, relative to the total weight of the composition.
- Suitable disintegrants include, for example, agar-agar, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, povidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, clays, other algins, other celluloses, gums, and mixtures thereof.
- the disintegrant is crospovidone.
- the disintegrant is croscarmellose sodium.
- Suitable lubricants include, for example, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, syloid silica gel (AEROSIL 200, W.R. Grace Co., Baltimore, Md.
- AEROSIL 200 AEROSIL 200, W.R. Grace Co., Baltimore, Md.
- Suitable anti-caking additives include, for example, calcium silicate, magnesium silicate, silicon dioxide, colloidal silicon dioxide, talc, and mixtures thereof.
- Suitable anti-microbial additives that may be used, e.g., as a preservative for the linaclotide compositions, include, for example, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, butyl paraben, cetylpyridinium chloride, cresol, chlorobutanol, dehydroacetic acid, ethylparaben, methylparaben, phenol, phenylethyl alcohol, phenoxyethanol phenylmercuric acetate, phenylmercuric nitrate, potassium sorbate, propylparaben, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimersol, thymo, and mixtures thereof.
- Suitable coating additives include, for example, sodium carboxymethyl cellulose, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methyl cellulose phthalate, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, and mixtures thereof.
- coating additives are selected from sodium carboxymethyl cellulose, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, and mixtures thereof.
- suitable additives for the linaclotide composition include one or more of sucrose, talc, magnesium stearate, crospovidone or BHA.
- suitable coating additives for the linaclotide composition include one or more of magnesium stearate, crospovidone or BHA.
- the composition comprises linaclotide and a hydrolysis product, e.g., a hydrolysis product comprising or having a structure of:
- the composition can contain any desired concentration of the hydrolysis product. In some embodiments, the composition comprises less than 10 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 7 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 6 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 4 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 1 wt.
- the composition comprises between 0.01 and 10 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 7 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.05 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 4 wt. % of the hydrolysis product.
- the composition comprises between 0.5 and 4 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 4 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 2.5 wt.
- the composition comprises between 0.05 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the hydrolysis product.
- the composition comprises linaclotide and a formaldehyde imine product, e.g., a formaldehyde imine product comprising or having a structure of:
- the composition can contain any desired concentration of the formaldehyde imine product. In some embodiments, the composition comprises less than 10 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 7 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 6 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 3 wt. % of the formaldehyde imine product.
- the composition comprises less than 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 1 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.01 and 10 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 7 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.05 and 5 wt. % of the formaldehyde imine product.
- the composition comprises between 0.5 and 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the formaldehyde imine product.
- the composition comprises between 0.5 and 3 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 3 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 2.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the formaldehyde imine product.
- the composition comprises between 0.05 and 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the formaldehyde imine product.
- the composition comprises linaclotide and an oxidation product, e.g., an oxidation product comprising or having a structure of:
- the composition comprises linaclotide and an oxidation product having the depicted structure but wherein oxidation occurs at any one or more of the six depicted cysteinyl sulfurs.
- the composition can contain any desired concentration of the oxidation product. In some embodiments, the composition comprises less than 10 wt. % of the oxidation product. In some embodiments, the composition comprises less than 7 wt. % of the oxidation product. In some embodiments, the composition comprises less than 6 wt. % of the oxidation product. In some embodiments, the composition comprises less than 5 wt. % of the oxidation product. In some embodiments, the composition comprises less than 4 wt. % of the oxidation product.
- the composition comprises less than 3 wt. % of the oxidation product. In some embodiments, the composition comprises less than 2 wt. % of the oxidation product. In some embodiments, the composition comprises less than 1 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.01 and 10 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.01 and 7 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.01 and 5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.05 and 5 wt. % of the oxidation product.
- the composition comprises between 0.5 and 5 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 4 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 4 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 4 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 3 wt. % of the oxidation product.
- the composition comprises between 1 and 3 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 2.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.05 and 2 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the oxidation product.
- the composition comprises between 1 and 2 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the oxidation product.
- the composition comprises linaclotide and an acetylation product, e.g., an acetylation product comprising or having:
- the composition can contain any desired concentration of the acetylation product. In some embodiments, the composition comprises less than 10 wt. % of the acetylation product. In some embodiments, the composition comprises less than 7 wt. % of the acetylation product. In some embodiments, the composition comprises less than 6 wt. % of the acetylation product. In some embodiments, the composition comprises less than 5 wt. % of the acetylation product. In some embodiments, the composition comprises less than 4 wt. % of the acetylation product. In some embodiments, the composition comprises less than 3 wt. % of the acetylation product. In some embodiments, the composition comprises less than 2 wt.
- the composition comprises less than 1 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.01 and 10 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 7 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 5 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 5 wt. % of the acetylation product.
- the composition comprises between 0.1 and 4 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 4 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 4 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 3 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 3 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 2.5 wt.
- the composition comprises between 0.5 and 2.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 2.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 2 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the acetylation product.
- the composition comprises between 0.5 and 1.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the acetylation product.
- the composition comprises linaclotide and any desired concentration of multimers. In some embodiments, the composition comprises less than 10 wt. % of multimer(s). In some embodiments, the composition comprises less than 7 wt. % of multimer(s). In some embodiments, the composition comprises less than 6 wt. % of multimer(s). In some embodiments, the composition comprises less than 5 wt. % of multimer(s). In some embodiments, the composition comprises less than 4 wt. % of multimer(s). In some embodiments, the composition comprises less than 3 wt. % of multimer(s). In some embodiments, the composition comprises less than 2 wt. % of multimer(s).
- the composition comprises less than 1 wt. % of multimer(s). In some embodiments, the composition comprises between 0.01 and 10 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 7 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 5 wt. % of multimer(s). In some embodiments, the composition comprises between 1 and 5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 4 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 4 wt.
- the composition comprises between 1 and 4 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 3 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 3 wt. % of multimer(s). In some embodiments, the composition comprises between 1 and 3 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 2.5 wt. %, of multimer(s). In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of multimer(s). In some embodiments, the composition comprises between 1 and 2.5 wt. % of multimer(s).
- the composition comprises between 0.1 and 2 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 2 wt. % of multimer(s). In % some embodiments, the composition comprises between 1 and 2 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 1 wt. % of multimer(s), in some embodiments, the composition comprises between 0.5 and 1 wt. % of multimer(s).
- the composition comprises an effective amount of linaclotide and any desired amount of reduced form linaclotide.
- reduced form linaclotide refers to linaclotide having no disulfide bonds between cysteine amino acids.
- the composition comprises less than 10 wt. % of reduced form linaclotide.
- the composition comprises less than 7 wt. % of reduced form linaclotide.
- the composition comprises less than 6 wt. % of reduced form linaclotide.
- the composition comprises less than 5 wt. % of reduced form linaclotide.
- the composition comprises less than 4 wt.
- the composition comprises less than 3 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 2 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 1 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.01 and 10 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 7 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 5 wt.
- the composition comprises between 1 and 5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 4 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 4 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 4 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 3 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 3 wt. % of reduced form linaclotide.
- the composition comprises between 1 and 3 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 2.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 2 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 2 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 2 wt.
- the composition comprises between 0.1 and 1.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 1 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 1 wt. % of reduced form linaclotide.
- the composition comprises an effective amount of linaclotide and any desired amount of scrambled form linaclotide.
- scrambled form linaclotide refers to linaclotide having disulfide bonds between Cys 1 and Cys 10 , between Cys 1 and Cys 13 , between Cys 1 and Cys 5 , between Cys 1 and Cys 2 , between Cys 2 and Cys 6 , between Cys 2 and Cys 13 , between Cys 2 and Cys 5 , between Cys 5 and Cys 6 , and/or between Cys 5 and Cys 10 .
- the composition comprises less than 10 wt. % of scrambled form linaclotide.
- the composition comprises less than 7 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 6 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 4 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 1 wt.
- the composition comprises between 0.01 and 10 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 7 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 4 wt.
- the composition comprises between 0.5 and 4 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 4 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 2.5 wt.
- the composition comprises between 0.5 and 2.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 2.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 1.5 wt.
- the composition comprises between 0.5 and 1.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 1 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 1 wt. % of scrambled form linaclotide.
- the composition comprises a total degradant concentration of less than about 10 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 8 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 7 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 6.5 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 6 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 5.5 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 5 wt. %.
- the composition comprises a total degradant concentration of less than about 4 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 3 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 2.5 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 2 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 1 wt. %.
- the composition can comprise any effective amount of linaclotide.
- the composition comprises from 0.05 g to 6 mg of linaclotide.
- the composition comprises from 0.1 ⁇ g to 6 mg of linaclotide.
- the composition comprises from 25 ⁇ g to 6 mg of linaclotide.
- the composition comprises from 25 ⁇ g to 2 mg of linaclotide, for example, from 50 ⁇ g to 1 mg of linaclotide.
- the composition comprises from 50 ⁇ g to 2 mg of linaclotide.
- the composition comprises from 0.1 ⁇ g to 90 ⁇ g of linaclotide.
- the composition comprises from 0.1 ⁇ g to 45 ⁇ g of linaclotide. In some embodiments, for example, the composition comprises from 0.1 ⁇ g to 25 ⁇ g of linaclotide. In some embodiments, the composition comprises 0.05 ⁇ g, 0.1 ⁇ g, 0.25 ⁇ g, 0.5 ⁇ g, 0.75 ⁇ g, 1 ⁇ g, 1.5 ⁇ g, 2 ⁇ g, 2.5 ⁇ g, 3 ⁇ g, 3.5 ⁇ g, 4 ⁇ g, 4.5 ⁇ g, 5 ⁇ g, 7.5 ⁇ g, 10 ⁇ g, 15 ⁇ g, 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 35 ⁇ g, 40 ⁇ g, 45 ⁇ g, 50 ⁇ g, 60 ⁇ g, 75 ⁇ g, 90 ⁇ g, 100 ⁇ g, 150 ⁇ g, 200 ⁇ g, 250 ⁇ g, 300 ⁇ g, 350 ⁇ g, 400 ⁇ g, 450 ⁇ g, 500 ⁇ g,
- the composition comprises from 100 ⁇ g to 600 ⁇ g of linaclotide. In some embodiments, the composition comprises 50 ⁇ g, 100 ⁇ g, 150 ⁇ g, 200 ⁇ g, 300 ⁇ g, 400 ⁇ g, 500 ⁇ g or 600 ⁇ g of linaclotide. In some embodiments, the composition comprises 75 ⁇ g, 150 ⁇ g, 300 ⁇ g, or 600 ⁇ g of linaclotide.
- the composition comprises 75 ⁇ g of linaclotide. In some embodiments, the composition comprises about 133 ⁇ g of linaclotide. In some embodiments, the composition comprises 150 ⁇ g of linaclotide. In some embodiments, the composition comprises about 266 ⁇ g of linaclotide. In some embodiments, the composition comprises 300 ⁇ g of linaclotide. In some embodiments, the composition comprises 600 ⁇ g of linaclotide. In some embodiments, the composition comprises 0.1 ⁇ g, 0.25 ⁇ g, 0.5 ⁇ g, or 0.75 ⁇ g of linaclotide. In some embodiments, the composition comprises 0.1 ⁇ g of linaclotide.
- the composition comprises 0.25 ⁇ g of linaclotide. In some embodiments, the composition comprises 0.5 ⁇ g of linaclotide. In some embodiments, for example, the composition comprises from 0.05 ⁇ g to 25 ⁇ g of linaclotide.
- the composition can be in any desired form, such as, for example, any desired solid form for oral administration.
- suitable solid dosage forms include, without limitation, tablets, capsules, gelcaps, sachets, pellets, caplets, granules, lozenges and bulk powders.
- the composition can be in the form selected from pellets, caplets, granules, lozenges and bulk powders.
- the composition is an immediate release composition (for example, an immediate release tablet or an immediate release capsule).
- the immediate release composition can have any desired dissolution rate.
- the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering a use environment.
- the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering a use environment.
- the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering a use environment.
- the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering a use environment.
- the composition releases at least 50% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering a use environment.
- the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution (e.g., phosphate buffer solution) having a pH of 4.5. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 4.5.
- an agitated buffer solution e.g., phosphate buffer solution
- the composition releases at least 50% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5.
- the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5.
- the buffer solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl.
- the composition releases at least 50% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl.
- the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within IS minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 50% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl.
- the composition releases at least 60% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl.
- the composition releases at least 90% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl.
- the solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8.
- the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8.
- the buffer solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes.
- the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes.
- the solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- compositions may be prepared in any suitable manner, such as described, for example, in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition): Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc. as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition).
- the compositions can be prepared using a method comprising: (a) providing a solution, e.g.
- an aqueous solution comprising linaclotide, or a pharmaceutically acceptable salt thereof, and stabilizing amount(s) of polymer, sterically hindered primary amine and/or cation component(s) and optionally other excipients; (h) applying the aqueous solution to a pharmaceutically acceptable filler to generate linaclotide-coated tiller (e.g. by spraying, mixing or coating the pharmaceutically acceptable filler with the coating solution); and optionally (c) compressing the linaclotide-coated filler into tablets.
- the method can optionally include one or more of: (i) blending the linaclotide-coated tiller with a pharmaceutically acceptable glidant, a pharmaceutically acceptable lubricant, or a pharmaceutically acceptable additive that acts as both a glidant and lubricant; (ii) blending the linaclotide-coated filler with tiller that is not linaclotide-coated, (iii) blending the linaclotide-coated filler with other additives; (iv) applying a pharmaceutically acceptable coating additive to the linaclotide-coated filler; and optionally (v) compressing the linaclotide-coated filler into tablets.
- the final pharmaceutical composition can be placed into any suitable formulation, such as capsules (e.g. gelatin capsules) or tablets.
- the composition can also be used to treat diseases, disorders, or conditions that are responsive to treatment with agonists of the GC-(C receptor.
- the composition can be used to treat any gastrointestinal disorders and/or conditions in a patient (e.g. mammal or human) or inflammation or pain associated therewith.
- Suitable such gastrointestinal disorders and conditions include, but are not limited to, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, dyspepsia (including functional dyspepsia or non-ulcer dyspepsia), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, for example, chronic constipation, opioid induced constipation, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders or a combination of symptoms thereof (such as a combination of irritable bowel syndrome and chronic constipation).
- a method is provided for treating gastrointestinal disorders in a patient (e.g., mammal or human) diagnosed with one or more gastrointestinal disorders or conditions, wherein
- a method for increasing intestinal motility in a patient in need thereof comprising administering an effective amount of the composition to the patient.
- Intestinal motility involves spontaneous coordinated dissentions and contractions of the stomach, intestines, colon and rectum to move food through the gastrointestinal tract during the digestive process.
- the methods may comprise administering a therapeutically effective amount of the pharmaceutical composition to a patient in need thereof.
- An effective amount of a composition comprising linaclotide or a pharmaceutically acceptable salt thereof required to achieve desired results (such as desired treatment and/or symptom relief) of a subject is dependent on several understood factors, such as the identity and severity of the disorder being treated, as well as the age, weight, etc. of the patient being treated.
- a subject or patient in whom administration of the pharmaceutical composition is an effective therapeutic regimen for a disease or disorder is preferably a human, but can be any animal, including a laboratory animal in the context of a clinical trial or screening or activity experiment.
- the methods, compounds and compositions described herein are particularly suited for administration to any animal, particularly a mammal, and including, but by no means limited to, humans, rodents and non-rodents, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats. etc. avian species, such as chickens, turkeys, songbirds, etc., e.g., for veterinary medical use.
- the effective dose range of linaclotide for adult humans is from 25 ⁇ g to 6 mg per day orally. In some embodiments, the dose range is 25 ⁇ g to 2 mg per day orally. In some embodiments, the dose range for adult humans is 50 ⁇ g to 1 mg per day orally (e.g., 50 ⁇ g, 100 ⁇ g, 150 ⁇ g, 200 ⁇ g, 250 ⁇ g, 300 ⁇ g, 350 ⁇ g, 400 ⁇ g, 450 ⁇ g, 500 ⁇ g, 550 ⁇ g, 600 ⁇ g, 650 ⁇ g, 700 ⁇ g, 750 ⁇ g, 800 ⁇ g, 850 ⁇ g, 900 ⁇ g, 950 ⁇ g or 1 mg).
- 50 ⁇ g to 1 mg per day orally e.g., 50 ⁇ g, 100 ⁇ g, 150 ⁇ g, 200 ⁇ g, 250 ⁇ g, 300 ⁇ g, 350 ⁇ g, 400 ⁇ g, 450 ⁇ g, 500 ⁇ g, 550
- the dose range is 100 ⁇ g to 600 ⁇ g per day orally. In some embodiments, the dose is 50 ⁇ g, 100 ⁇ g, 150 ⁇ g, 200 ⁇ g, 300 ⁇ g, 400 ⁇ g, 500 ⁇ g or 600 ⁇ g linaclotide per day orally. In some embodiments, the dose is 50 ⁇ g linaclotide per day orally. In some embodiments, the dose is 100 ⁇ g linaclotide per day orally. In some embodiments, the dose is 150 ⁇ g linaclotide per day orally. In some embodiments, the dose is 200 ⁇ g linaclotide per day orally. In some embodiments, the dose is 300 ⁇ g linaclotide per day orally.
- the dose is 400 ⁇ g linaclotide per day orally. In some embodiments, the dose is 500 ⁇ g linaclotide per day orally. In some embodiments, the dose is 600 ⁇ g linaclotide per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.05 ⁇ g to 2 mg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.05 ⁇ g to 100 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 ⁇ g to 90 ⁇ g per day orally.
- the effective pediatric dose range of linaclotide is from 0.1 ⁇ g to 50 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 ⁇ g to 15 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 ⁇ g to 10 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 ⁇ g to 5 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 ⁇ g to 1 ⁇ g per day orally.
- the effective pediatric dose range of linaclotide is from 0.1 ⁇ g to 0.5 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.25 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.5 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 3.5 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 15 ⁇ g per day orally.
- the effective pediatric dose range of linaclotide is 45 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 60 ⁇ g per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 90 ⁇ g per day orally.
- the unit dosage form and daily dose are equivalent. In some embodiments, the unit dosage form is administered with food at anytime of the day, without food at anytime of the day, with food after an overnight fast (e.g., with breakfast). In some embodiments, the unit dosage form is administered once a day, twice a day or three times a day. In some embodiments, one, two or three unit dosage forms will contain the daily oral dose of linaclotide. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity.
- the compositions are administered as a monotherapy. In some embodiments, the composition consists essentially of an effective amount of linaclotide. In some embodiments, the composition consists of an effective amount of linaclotide.
- compositions are administered as part of a combination therapy.
- a composition may be used in combination with other drugs or therapies that are used in the treatment, prevention, suppression, and/or amelioration of the diseases or conditions for which compounds of the invention are useful.
- the linaclotide can be co-administered or co-formulated with other medications.
- the linaclotide composition can be co-administered with other medications used to treat gastrointestinal disorders including but not limited to acid suppressing agents such as Histamine-2 receptor agonists (H2As) and/or proton pump inhibitors (PPIs).
- H2As Histamine-2 receptor agonists
- PPIs proton pump inhibitors
- Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the invention.
- a pharmaceutical unit dosage form containing such other drugs in addition to the compound of the invention may be employed.
- the pharmaceutical compositions of the present invention include those that also contain one or more other active components, in addition to a compound of invention.
- linaclotide composition Several methods can be used for evaluating the bioactivity of the linaclotide composition, including, but not limited to, immunoassays (e.g., enzyme-linked immunosorbent assay), radioimmuno assays, immunoradiometric assays, gel electrophoresis (e.g., SDS-PAGE), high performance liquid chromatography (HPLC), and/or high performance capillary electrophoresis (HPCE).
- immunoassays e.g., enzyme-linked immunosorbent assay
- radioimmuno assays e.g., immunoradiometric assays
- gel electrophoresis e.g., SDS-PAGE
- HPLC high performance liquid chromatography
- HPCE high performance capillary electrophoresis
- the bioactivity of the composition is assessed by a method comprising fixing linaclotide, incubating linaclotide with guanylate cyclase C (GCC), incubating GCC bound linaclotide with antibodies against GCC, incubating GCC antibody-bound linaclotide with fluorescently labeled antibodies against GCC antibodies, and detecting the linaclotide bound to the GCC antibodies by measuring the fluorescence intensity using a plate reader. The drug concentration can then be calculated based on the fluorescence reading of the solution.
- GCC guanylate cyclase C
- the bioactivity of the linaclotide compositions can be assessed and quantified using the following method, though other methods are available.
- the composition is added to a volumetric flask containing 60 ml of phosphate buffer having a pH of 4.5, and the flask is shaken for 60 minutes. 0.2 ml of the supernatant is then removed, and is added into one or more wells of a 96-well plate that is coated with GCC. The plate is sealed and incubated at 37° C. for 2 hr. At the end of incubation, the sample is removed and the plate is washed with phosphate buffered saline (PBS).
- PBS phosphate buffered saline
- the bound linaclotide is then incubated for 1 hour, at room temperature, with GCC (such as is available from Sigma-Aldrich Inc.) labeled with fluorescein isocyanate (FITC) in blocking buffer. After incubation, the well is washed with PBS. The fluorescence intensity of the end product is detected, for example, by using a plate reader. The linaclotide concentration is then calculated based on the fluorescence reading of the solution.
- GCC such as is available from Sigma-Aldrich Inc.
- FITC fluorescein isocyanate
- linaclotide refers to a peptide that consists of the amino acid sequence Cys 1 Cys 2 Glu 3 Tyr 4 Cys 5 Cys 6 Asn 7 Pro 8 Ala 9 Cys 10 Thr 11 Gly 12 Cys 13 Tyr 14 (“linaclotide”, SEQ ID NO: 1), as well as any pharmaceutically acceptable salts or hydrates thereof, any isolated and purified forms thereof, or disulfide forms thereof.
- “Disulfide forms” of linaclotide are defined herein as linaclotide having one, two, or three of the following disulfide bonds between cysteinyl amino acids: a disulfide bond between Cys 1 and Cys 6 , a disulfide bond between Cys 2 and Cys 10 , and/or a disulfide bond between Cys 5 and Cys 13 .
- disulfide forms of linaclotide can comprise disulfide bonds between Cys 1 and Cys 6 and between Cys 2 and Cys 10 .
- disulfide forms of linaclotide can comprise disulfide bonds between Cys 1 and Cys 6 and between Cys 5 and Cys 13 .
- disulfide forms of linaclotide can comprise disulfide bonds between Cys 2 and Cys 10 and between Cys 5 and Cys 13 .
- isolated and purified means at least 95 percent pure (for example, at least 96% pure, at least 97% pure, at least 98% pure, or even at least 99% pure), as measured, for example, by chromatographic purity using HPLC.
- released from when referring to the release of linaclotide from the composition, unless otherwise indicated, is used herein to mean that the linaclotide no longer remains in a composition form.
- stabilizing agent refers to a polymer, sterically hindered primary amine (e.g., amino acid), or cation (e.g., metal cation) component of the composition which is included in the composition in a stabilizing amount.
- a polymeric stabilizing agent is a polymer that is included in the composition in a stabilizing amount.
- a sterically hindered primary amine stabilizing agent is a sterically hindered primary amine that is included in the composition in a stabilizing amount.
- a cationic stabilizing agent is a cation that is included in the composition in a stabilizing amount.
- stabilizing amount refers to a concentration, within the composition, of a polymer, sterically hindered primary amine (e.g., amino acid), or cation component at which the component increases the stability of linaclotide in the composition, as compared to a similar composition not having a stabilizing amount of the same component.
- the term “entry into a use environment” means contact of the composition with saliva, gastric fluids, or enteric fluids of the patient to whom it is administered, or with a fluid intended to simulate saliva, gastric fluid, or enteric fluid for example an agitated buffer solution have a pH of 4.5, an agitated 0.1 N HCl solution, an agitated buffer solution having a pH of 6.8, or an agitated solution of simulated intestinal fluid without enzymes.
- agitated when used to refer to a solution means that the solution is agitated using USP Apparatus II at 50 rpm. USP Apparatus I at 100 rpm, or the like.
- therapeutically effective amount means the amount of a linaclotide or a pharmaceutically acceptable salt thereof that, when administered to a mammal for treating a state, disorder or condition, is sufficient to effect a treatment (as defined below).
- the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, sex, weight, physical condition and responsiveness of the mammal to be treated.
- a therapeutically effective amount of linaclotide, or its pharmaceutically acceptable salt or hydrate can be an amount effective to treat gastrointestinal disorders, including irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation and/or dyspepsia.
- “pharmaceutically acceptable” means biologically or pharmacologically compatible for in dry use in animals or humans, and preferably means, approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- the term “treat”, in all its verb forms, is used herein to mean to relieve, alleviate, prevent, and/or manage at least one symptom of a disorder in a subject, the disorder including, for example, a gastrointestinal disorder, such as, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation, dyspepsia, or a combination of symptoms thereof.
- a gastrointestinal disorder such as, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation, dyspepsia, or a combination of symptoms thereof.
- the term “treat” also denotes, to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease.
- treatment means the act of “treating” as defined above.
- additives refers to a pharmaceutically acceptable additive.
- Pharmaceutically acceptable additives include, without limitation, binders, disintegrants, dispersing additives, lubricants, glidants, antioxidants, coating additives, diluents, surfactants, flavoring additives, humectants, absorption promoting additives, controlled release additives, anti-caking additives, anti-microbial agents (e.g. preservatives), colorants, desiccants, plasticizers and dyes.
- an “excipient” is any pharmaceutically acceptable additive, filler, binder or agent.
- stressed conditions refer to 40° C. and 75% relative humidity (RH).
- the terms “about” and “approximately” mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend, in part, on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per practice in the art. Alternatively, “about” with respect to the compositions can mean plus or minus a range of up to 20%, preferably up to 10%. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Particular values are described in the application and claims, unless otherwise stated the term “about” means within an acceptable error range for the particular value.
- composition includes linaclotide and other desired pharmaceutically inactive additives, excipients, and/or components (e.g., polymers, sterically hindered primary amines, cations, filling agents, binders, carriers, excipients, diluents, disintegrating additives, lubricants, solvents, dispersants, coating additives, absorption promoting additives, hydrolysis products, formaldehyde imine products, oxidation products, acetylation products, deamidation products, multimers, controlled release additives, anti-caking additives, anti-microbial additives, preservatives, sweetening additives, colorants, flavors, desiccants, plasticizers, dyes, or the like), and no other active pharmaceutical ingredient(s).
- linaclotide e.g., polymers, sterically hindered primary amines, cations, filling agents, binders, carriers, excipients, diluents, disintegrating additives, lub
- linaclotide compositions (0.15 mg theoretical, actual 0.135 mg) were packaged into a HDPE bottle with desiccant, and stored under at 40° C./75% RH (“stressed conditions”). The amount of linaclotide was assayed initially and after 3, 6, 9, 12, or 18 months of storage at stressed conditions.
- the concentration of linaclotide was analyzed and quantified using an HPLC method with the following mobile phase gradient: Mobile phase A: 50 mM of sodium perchlorate in a solvent containing 76% water and 24% acetonitrile and 0.1% of trifluoroacetic acid; Mobile phase B: 50 mM of sodium perchlorate in a solvent containing 5% water and 95% acetonitrile and 0.1% of trifluoroacetic acid; Flow rate: 0.6 ml/min; Column: YMC Pro C 18, 150 mm ⁇ 3 mm ID, 3 ⁇ m or equivalent; Column temperature: 40° C.; Fluorescence detection: excitation: 274 nm; emission: 303 nm; Injection volume: 100 ⁇ l.
- Degradant analysis was performed using an HPLC method employing the following conditions: Mobile phase A: Water: acetonitrile 98:2, with 0.1% (v/v) of trifluoroacetic acid; Mobile phase B: Water: acetonitrile 5:95, with 0.1% (v/v) of trifluoroacetic acid; Flow rate: 0.6 ml/min; Column: YMC Pro C18, 150 mm ⁇ 3 mm ID, 3 ⁇ m or equivalent; Column temperature: 40° C.; UV detection: excitation: 220 nm; Injection volume: 50 ⁇ l.
- the percentage amounts of degradants in the composition were calculated by quantifying the area of all peaks in the HPLC chromatogram to obtain the “total peak area”, and dividing the peak area of each degradant by the total peak area.
- the dissolution performance of the composition was assessed in phosphate buffer, pH 4.5 using USP Apparatus II (Paddle, 50 rpm).
- HCl solution 1000 g was weighed in a container and PVP (50% of theoretical weight), linaclotide, calcium chloride, and leucine were added into the HCl solution while mixing, until a clear coating solution was obtained.
- Isomalt and PVP 50% of theoretical weight
- the coating solution was top sprayed on the fluidized powder at a speed of 10 g/min and the granules were dried for 20 minutes at a product temperature of 40° C. The granules were discharged and sieved through a 20 mesh hand screen.
- the linaclotide granules, isomalt, and crospovidone were weighed, screened together through a 20 mesh hand screen, charged into a V-blender shell (available from Patterson-Kelly, East Stroudsburg, Pa.), and mixed for 20 minutes.
- Talc was weighed and screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 minutes.
- Magnesium stearate was weighed, screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 minutes.
- the blend was discharged and added into the hopper of a tablet press.
- the linaclotide tablets were compressed with a weight of 200 mg and hardness of 4-6 kp.
- the composition of resulting linaclotide IR tablets of different strengths is shown in Tables 1 and 2.
- Linaclotide IR Tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Isomalt 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Isomalt 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 4 were prepared in the same manner as described in Example 1.
- the dissolution and stability performance of the linaclotide IR tablets (0.135 mg/200 mg, HDPE bottle with desiccant) was evaluated at 40° C./75% RH, as is illustrated in Table 5.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Isomalt 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 6 were prepared in the manner described in Example 1. The dissolution and stability of linaclotide IR tablets (0.135 mg/200 mg, HDPE bottle with desiccant) was evaluated at 40° C./75% RH, as is illustrated in Table 7.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Dicalcium phosphate 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 8 were prepared in the manner described in Example 1. The dissolution and stability of linaclotide IR tablets (0.15 mg/200 mg) was evaluated at 40° C./75% RH, as is illustrated in Table 9.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Microcrystalline cellulose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 10 were prepared in the manner described in Example 1. The dissolution and stability of linaclotide IR tablets (0.15 mg/200 mg) was evaluated at 40° C./75% RH, as is illustrated in Table 11.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Mannitol 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR capsules comprising components as shown in Table 12 were prepared using a process similar to that described in Example 1 but without use of the tablet press.
- Linaclotide beads (600 mcg/225 mg) % QUANTITY/UNIT COMPONENTS W/W (mg) Linaclotide 0.267 0.600 HPMC (Methocel E5 Premium LV) 0.7 1.575 Calcium Chloride Dihydrate 1.54 3.47 Leucine 0.68 1.54 Microcrystalline Cellulose, NF 96.8 217.8 (Celphere CP305 beads) Hydrochloric acid, NF — — (36.5-38%) Purified water, USP — — TOTAL 100.0 225.0
- Linaclotide IR tablets comprising components as shown in Table 14 were prepared as described in Example 1.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.15 0.75 Isomalt 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Isomalt 134.1 670.5 Croscarmellose sodium 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7
- Linaclotide IR capsules comprising components as shown in Table 16 may be prepared using a process similar to that described in Example 6.
- Linaclotide IR capsules comprising components as shown in Table 17 may be prepared using a process similar to that described in Example 6.
- Linaclotide IR capsules comprising components as shown in Table 18 may be prepared using a process similar to that described in Example 6.
- Linaclotide IR tablets comprising components as shown in Table 19 may be prepared as described in Example 1.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 PVA 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 20 may be prepared as described in Example 1 using pregelatinized starch as a granular filling agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75
- Pregelatinized starch 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11
- Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 21 may be prepared as described in Example 1 using trehalose as a granular filling agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Trehalose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 22 may be prepared as described in Example 1 using erythitol as a granular filling agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Erythitol 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 23 may be prepared as described in Example 1 using maltitol as a granular filling agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Maltitol 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 24 may be prepared as described in Example 1 using lactose as a granular filling agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Lactose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 25 may be prepared as described in Example 1 using glucose as a granular filling agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Glucose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 26 may be prepared as described in Example 1 using isoleucine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Isoleucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 27 may be prepared as described in Example 1 using asparagine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Asparagine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 28 may be prepared as described in Example 1 using glutamine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Glutamine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 29 may be prepared as described in Example 1 using glutamic acid as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Glutamic acid 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 30 may be prepared as described in Example 1 using histidine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Histidine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 31 may be prepared as described in Example 1 using glycine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Glycine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 32 may be prepared as described in Example 1 using cysteine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Cysteine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 33 may be prepared as described in Example 1 using alanine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Alanine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 34 may be prepared as described in Example 1 using serine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Serine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 35 may be prepared as described in Example 1 using threonine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Threonine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 36 may be prepared as described in Example 1 using tyrosine as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Tyrosine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 37 may be prepared as described in Example 1 using proline as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Proline 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 38 may be prepared as described in Example 1 using tryptophan as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Tryptophan 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 39 may be prepared as described in Example 1 using KCl as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Potassium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 40 may be prepared as described in Example 1 using NaCl as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Sodium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 41 may be prepared as described in Example 1 using MgCl 2 as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Magnesium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 42 may be prepared as described in Example 1 using ZnCl 2 as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Zinc chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 43 may be prepared as described in Example 1 using BaCl 2 as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Barium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 44 may be prepared as described in Example 1 using MnCl 2 as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Manganese chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 45 may be prepared as described in Example 1 using a polaxomer as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Poloxamer (Pluronic ®) 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 46 may be prepared as described in Example 1 using gelatin as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Gelatin 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 47 may be prepared as described in Example 1 using chitosan as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Chitosan 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 48 may be prepared as described in Example 1 using cyclodextran as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Cyclodextrin 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 49 may be prepared as described in Example 1 using guar gum as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Guar gum 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 50 may be prepared as described in Example 1 using xanthan gum as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Xanthan gum 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 51 may be prepared as described in Example 1 using dextran as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Dextran 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 52 may be prepared as described in Example 1 using dextrin as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Dextrin 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 53 may be prepared as described in Example 1 using polyethylene polypropylene oxide as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polyethylene 2.2 11 polypropylene oxide Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 54 may be prepared as described in Example 1 using polyacrylic acid as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polyacrylic acid 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 55 may be prepared as described in Example 1 using hydroxylpropyl cellulose as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Hydroxylpropyl cellulose 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 56 may be prepared as described in Example 1 using methyl cellulose as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Methyl cellulose 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 57 may be prepared as described in Example 1 using hydroxylpropyl methylcellulose as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Hydroxylpropyl methylcellulose 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 58 may be prepared as described in Example 1 using Poly(sodium vinylsulfonate) as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Poly(sodium vinylsulfonate) 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 59 may be prepared as described in Example 1 using polyethylene glycol as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polyethylene glycol 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 60 may be prepared as described in Example 1 using poly(arginine) as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Poly(arginine) 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 61 may be prepared as described in Example 1 using polycarbophil as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polycarbophil 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- Linaclotide IR tablets comprising components as shown in Table 62 may be prepared as described in Example 1 using polyvinyl pyrrolidone-co vinyl acetate as a stabilizing agent.
- Linaclotide IR tablet 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 polyvinyl pyrrolidone- 2.2 11 co vinyl acetate Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process.
- the linaclotide hydrolysis product occurs as a transformation of Asn in the 7 position to Asp (the numbering of linaclotide starts with 1 at the N-terminal Cys). Its structure is depicted below:
- the linaclotide hydrolysis product has been independently synthesized for confirmation of identity using standard solid phase peptide synthesis techniques.
- the linaclotide hydrolysis product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by recombinant expression of a nucleic acid encoding the linaclotide hydrolysis product (Cys Cys Glu Tyr Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr, SEQ ID NO: 2), optionally followed by oxidation of the cysteine residues to form the disulfide linkages.
- the formaldehyde imine product occurs as the addition of an imine to the N-terminal Cys (Cys 1) via a formaldehyde-mediated reaction.
- Cys 1 N-terminal Cys 1
- a proposed structure of the product is depicted below:
- the linaclotide formaldehyde imine product has been independently synthesized for confirmation of identity by reacting linaclotide with formaldehyde (1:5 molar ratio) in absolute ethanol at room temperature for 4 days.
- the formaldehyde imine product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by chemical peptide synthesis or recombinant expression of a nucleic acid encoding linaclotide followed by formylation as described herein or by other methods known in the art, optionally followed by oxidation of the cysteine residues to form the disulfide linkages.
- the linaclotide oxidation product has a molecular weight of 1542.8.
- the oxidation product most likely forms as the addition of a single oxygen atom to one of the six cysteinyl sulfurs in linaclotide.
- One potential structure of the product is depicted below, although one of skill in the art will recognize that the oxygen atom may be attached to any of the other five sulfurs:
- the linaclotide oxidation product has been produced by reacting linaclotide with hydrogen peroxide (3% aqueous) at room temperature or 40° C. for up to 24 hours.
- the resulting product is enriched in the oxidation product by 1-10%.
- the linaclotide oxidation product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by chemical peptide synthesis or recombinant expression of a nucleic acid encoding linaclotide followed by oxidation of the cysteine residues to form the disulfide linkages followed by reacting linaclotide with hydrogen peroxide or similar oxidizing reagent to form the linaclotide oxidation product.
- compositions may be prepared which have the molar ratios of stabilizing agent(s) to linaclotide set forth in Table 63.
- compositions may be prepared which have the molar ratios of filling agent(s) to linaclotide set forth in Table 64.
- HCl solution 1000 g was weighed in a container and polyvinyl pyrrolidone (PVP) (50% of theoretical weight), linaclotide, calcium chloride, and leucine were added into the HCl solution while mixing, until a clear coating solution was obtained.
- PVP polyvinyl pyrrolidone
- Isomalt and PVP 50% of theoretical weight were charged into the bowl of the fluid bed (Glatt GCGP 3.0, Glatt, Ramsey N.J.) and mixed for 2 min by fluidizing the powder.
- the coating solution was top sprayed on the fluidized powder at a speed of 10 g/min and the granules were dried for 20 min at a product temperature of 40° C.
- the granules were discharged and sieved through a 20 mesh hand screen.
- the linaclotide granules, isomalt, and croscarmellose sodium were weighed, screened together through a 20 mesh hand screen, charged into a V-blender shell (Patterson-Kelly, East Stroudsburg, Pa.) and mixed for 20 min.
- Talc was weighed and screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 min.
- Magnesium stearate was weighed, screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 min.
- the blend was discharged and added into the hopper of a tablet press.
- the linaclotide tablets were compressed with a weight of 75 mg and hardness of 4-6 kp.
- the composition of resulting linaclotide IR tablets of different strengths is shown in Tables 65 and 66.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Isomalt (powder) 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Croscarmellose sodium 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5.1 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 67 may be prepared as described in Example 60 using pregelatinized starch as a tablet filling agent and crospovidone as the disintegrant. The composition of resulting linaclotide IR tablets of different strengths is shown in 68.
- Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Isomalt (powder) 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Pregelatinized starch 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 69 may be prepared as described in Example 60 using dicalcium phosphate as a granular tilling agent and crospovidone as the disintegrant. The composition of resulting linaclotide IR tablets of different strengths is shown in 70.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Dicalcium phosphate 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 71 may be prepared as described in Example 62 using Microcrystalline cellulose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 72.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Microcrystalline cellulose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 73 may be prepared as described in Example 62 using Mannitol as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 74.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 75 may be prepared as described in Example 64 using PVA as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 76.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 77 may be prepared as described in Example 65 using Trehalose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 78.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Trehalose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 79 may be prepared as described in Example 65 using hydropropyl methyl cellulose as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 80.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Hydropropyl methyl cellulose 2 26.7 (HPMC) Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 81 may be prepared as described in Example 66 using Erythitol as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 82.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Erythitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 83 may be prepared as described in Example 68 using Maltitol as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 84.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Maltitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 85 may be prepared as described in Example 69 using lactose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 86.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Lactose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 87 may be prepared as described in Example 70 using glucose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 88.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Glucose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 89 may be prepared as described in Example 65 using isoleucine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 90.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Isoleucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 91 may be prepared as described in Example 72 using Asparagine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 92.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Asparagine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 93 may be prepared as described in Example 73 using Glutamine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 94.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Glutamine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 95 may be prepared as described in Example 74 using glycine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 96.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Glycine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 97 may be prepared as described in Example 75 using histidine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 98.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Histidine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 99 may be prepared as described in Example 76 using tyrosine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 100.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Tyrosine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 101 may be prepared as described in Example 77 using lysine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 102.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Lysine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 103 may be prepared as described in Example 78 using cystine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 104.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Cystine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 105 may be prepared as described in Example 79 using alanine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 106.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Alanine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 107 may be prepared as described in Example 80 using serine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 108.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Serine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Croscarmellose sodium 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 109 may be prepared as described in Example 81 using threonine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 110.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Threonine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 111 may be prepared as described in Example 82 using proline as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 112.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Proline 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 113 may be prepared as described in Example 83 using tryptophan as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 114.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Tryptophan 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 115 may be prepared as described in Example 84 using leucine and potassium chloride as stabilizing agents. The composition of resulting linaclotide IR tablets of different strengths is shown in 116.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Potassium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 117 may be prepared as described in Example 85 using sodium chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 118.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Sodium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 119 may be prepared as described in Example 86 using magnesium chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 120.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Magnesium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 121 may be prepared as described in Example 87 using iron chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 122.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Iron chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 123 may be prepared as described in Example 88 using copper chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 124.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Copper chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 125 may be prepared as described in Example 89 using zinc chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 126.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Zinc chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 127 may be prepared as described in Example 90 using aluminum chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 128.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Aluminum chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 129 may be prepared as described in Example 91 using barium chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 130.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Barium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 131 may be prepared as described in Example 92 using Manganese chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 132.
- Linaclotide Table 11 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Manganese chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 133 may be prepared as described in Example 64 using Pluronic as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 134.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Pluronic 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 135 may be prepared as described in Example 94 using gelatin as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 136.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Gelatin 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 137 may be prepared as described in Example 95 using chitosan as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 138.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Chitosan 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 139 may be prepared as described in Example 96 using cyclodextrin as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 140.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Cyclodextrin 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 141 may be prepared as described in Example 97 using guar gum as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 142.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Guar gum 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 143 may be prepared as described in Example 98 using Xanthan gum as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 144.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Xanthan gum 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 145 may be prepared as described in Example 99 using Dextran as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 146.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Dextran 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 147 may be prepared as described in Example 100 using Dextrin as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 148.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Dextrin 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 149 may be prepared as described in Example 101 using Polyethylene polypropylene oxide as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 150.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyethylene 2 26.7 polypropylene oxide Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 151 may be prepared as described in Example 102 using polyacrylic acid as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 152.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyacrylic acid 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 153 may be prepared as described in Example 103 using Hydroxypropyl cellulose as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 154.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Hydroxypropyl cellulose (HPC) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 155 may be prepared as described in Example 104 using methyl cellulose as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 156.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Methyl cellulose 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 157 may be prepared as described in Example 105 using Poly(sodium vinylsulfonate) as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 158.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Poly(sodium vinylsulfonate) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 159 may be prepared as described in Example 106 using polyethylene glycol as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 160.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyethylene glycol 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 161 may be prepared as described in Example 107 using Polycarbophil as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 162.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polycarbophil 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
- Pediatric linaclotide IR tablets comprising components as shown in Table 163 may be prepared as described in Example 108 using Polyvinyl pyrrolidone-co vinyl acetate as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 164.
- Linaclotide IR tablet 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl pyrrolidone- 2 26.7 co vinyl acetate Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mechanical Engineering (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.
Description
- This application is a continuation application of U.S. application Ser. No. 12/851,330, filed on Aug. 5, 2010, which claims priority under 35 USC §119(e) to U.S. Provisional Patent Application Ser. No. 61/231,725, filed on Aug. 6, 2009, the entire contents of which is hereby incorporated by reference.
- This application incorporates by reference in its entirety the Sequence Listing entitled “IW080US1_ST25.txt” (2.20 kilobytes) which was created Feb. 19, 2013 and filed electronically herewith.
- The present invention relates to stable formulations comprising linaclotide, processes for making the compositions and methods of treating conditions using the compositions.
- U.S. Pat. Nos. 7,304,036 and 7,371,727 disclose peptides that act as agonists of the guanylate cyclase C (GC-C) receptor for the treatment of gastrointestinal disorders. One particular peptide disclosed is linaclotide, which consists of the following amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 1). The '036 and '727 patents also disclose methods for preparing linaclotide and related peptides. The contents of these patents are incorporated herein by reference in their entirety.
- There remains a need for improved formulations of linaclotide, and pharmaceutically acceptable salts thereof, having improved stability and performance properties.
- The present invention seeks to provide such improved formulations of linaclotide, as well as processes for making the formulations and methods of treating gastrointestinal disorders by administering the formulations.
- In some embodiments, a stable pharmaceutical composition comprising linaclotide and a pharmaceutically acceptable carrier is provided.
- In some embodiments, a pharmaceutical composition of linaclotide is provided, wherein the composition comprises a stabilizing amount of a polymer, a stabilizing amount of a sterically hindered primary amine, a stabilizing amount of a cation, or a combination or mixture thereof.
- In some embodiments, an immediate release pharmaceutical composition comprising linaclotide, or a pharmaceutically acceptable salt thereof is provided.
- In some embodiments, a method of treating a gastrointestinal disorder comprising administering to a patient in need thereof, a therapeutically effective amount of the compositions is provided.
- Stable formulations of linaclotide are provided herein. In addition, methods of using the formulations to treat gastrointestinal disorders, including irritable bowel syndrome (“IBS”) (for example, constipation-predominant IBS) and/or constipation (for example, chronic constipation), and processes for making the compositions are provided.
- It has been found, in some embodiments, that the stability of linaclotide compositions can be increased or improved by including in the compositions a suitable amount of a polymer component, a sterically hindered primary amine (e.g., amino acid) component, and/or a cation (e.g., metal cation) component. These components increase or enhance the stability of a linaclotide composition, for example, by preventing, lessening, and/or decreasing degradation of linaclotide within the composition (for example, due to moisture-driven degradation reactions. e.g., hydrolysis, deamidation, and/or multimerization reactions). For instance, it has been found in some embodiments that addition or inclusion of a suitable amount of a cation (e.g. Mg2+, Ca2+, Zn2+) in the composition increases the stability of the composition against oxidative degradation of linaclotide. Moreover, it has been found in some embodiments that inclusion of a suitable amount of a sterically hindered primary amine (e.g., leucine) in the composition increases the stability of the composition against the formation of formaldehyde imine adducts of linaclotide. Moreover, it has been found in some embodiments that inclusion of both a sterically hindered primary amine (e.g. leucine) and a cation (e.g. Ca2+) in suitable amounts in the composition increases the stability of the composition against the formation of hydrolysis products of linaclotide.
- In addition, it has been found in some embodiments that inclusion of a suitable amount of a polymer (e.g. polyvinyl pyrrolidone or polyvinyl alcohol) in the composition increases the stability of the composition for example by decreasing the mobility and/or reactivity of linaclotide within the composition. e.g., by forming a complex or matrix (for example, a glassy and/or rigid matrix) with linaclotide (e.g., by vitrification reaction), by preventing or lessening hydrogen bond formation between linaclotide and water molecules, and/or by enhancing the three-dimensional structural integrity of linaclotide. In this regard, it has been found in some embodiments that combining linaclotide with specific amounts or ratios of polymer, sterically hindered primary amine and cation causes a synergistic enhancement or improvement in the stability of linaclotide within pharmaceutical compositions, for example as compared to pharmaceutical compositions not containing the polymer, sterically hindered primary amine and cation and/or the same concentrations of these components.
- Suitable polymers for inclusion in the composition are, for example, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxylpropyl methyl cellulose (tHPMC), hydroxylpropyl cellulose (HPC), methyl cellulose, methacrylate polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, guar gum, xanthan gum, polyethylene polypropylene oxide, poly(sodium vinylsulfonate), polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer (e.g., PLURONIC® products available from BASF), or a combination or mixture thereof. In some embodiments, the composition comprises a polymer selected from PVP, PVA, methacrylate polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, guar gum, xanthan gum, polyethylene polypropylene oxide, polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer, or a combination or mixture thereof. In some embodiments, the composition comprises PVP, PVA, or a mixture thereof. In some embodiments, the composition comprises PVP. In some embodiments, the composition comprises PVA. In some embodiments, the composition comprises methacrylate polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, xanthan gum, polyethylene polypropylene oxide, poly(sodium vinylsulfonate), polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer (e.g. PLURONIC® products available from BASF), or a combination or mixture thereof.
- The composition can contain any stabilizing amount of a polymer. In some embodiments, the composition comprises between 0.01 and 10 wt. % of a polymer. In some embodiments, the composition comprises between 2.5 and 10 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 5 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 4 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 3 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 2.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of a polymer. In some embodiments, the composition comprises between 1 and 2.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.01% and 2 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 2 wt. % of a polymer. In some embodiments, the composition comprises between 0.5 and 2 wt. % of a polymer. In some embodiments, the composition comprises between 1 and 2 wt. % of a polymer.
- In some embodiments, the composition comprises between 0.01 and 1.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 1.25 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 1 wt. % of a polymer. In some embodiments, the composition comprises between 0.1 and 1 wt. % of a polymer. In some embodiments, the composition comprises between 0.5 and 1 wt. % of a polymer. In some embodiments, the composition comprises between 0.01 and 0.5 wt. % of a polymer.
- Suitable sterically hindered primary amines for inclusion in the composition are, for example, naturally-occurring amino acids (e.g., alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine), synthetic amino acids (e.g., lanthionine, theanine or 1-amino cyclohexane), amino sugars (e.g., chitosan or glucosamine), or combination or mixtures thereof. In some embodiments, the composition comprises an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, asparagine, glutamine, glutamic acid, histidine, cysteine, alanine, serine, threonine, tyrosine, proline, tryptophan, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, isoleucine, methionine, or a combination or mixture thereof. In some embodiments, the composition comprises an amino acid selected from leucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises leucine, methionine, or a mixture thereof. In some embodiments, the composition comprises leucine, isoleucine, or a mixture thereof. In some embodiments, the composition comprises leucine, alanine, or a mixture thereof. In some embodiments, the composition comprises leucine. In some embodiments, the composition comprises isoleucine. In some embodiments, the composition comprises methionine. In some embodiments, the composition comprises alanine. In some embodiments, the composition comprises an amino acid selected from arginine, cysteine, glycine, lysine, proline, serine, or a mixture thereof. In some embodiments, the composition comprises 1-amino cyclohexane.
- The composition can comprise any stabilizing amount of a sterically hindered primary amine component. For example, the composition can comprise a molar ratio of sterically hindered primary amine (e.g., amino acid) to linaclotide between 100:1 and 1:100. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 1:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 90:1 and 2:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 80:1 and 5:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 70:1 and 10:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 60:1 and 20:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 50:1 and 30:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 40:1 and 20:1.
- In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 20:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 25:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 30:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 50:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 60:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 70:1.
- In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 5:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 10:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 20:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 25:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 30:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide of at least 40:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 5:1 and 1:1. In some embodiments, the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 1:100 and 1:1.
- In some embodiments, the composition comprises about 0.5 to about 10% by weight of a sterically hindered primary amine relative to the total weight of the pharmaceutical composition (e.g., solid oral dosage form or bead). In some embodiments, the composition comprises about 0.5 to about 7% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.5 to about 5% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.5 to about 4% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.5 to about 3% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.5 to about 2% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 5% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 4% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 3% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 0.75 to about 2% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 1 to about 5% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 1 to about 4% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 1 to about 3% by weight of a sterically hindered primary amine. In some embodiments, the composition comprises about 1 to about 2% by weight of a sterically hindered primary amine.
- Any suitable cation(s) can be included in the composition, for example, any suitable metal cation or organic cation. In some embodiments, the composition comprises a metal cation selected from calcium, potassium, magnesium, zinc, aluminum, iron, tin, manganese, chromium, cobalt, nickel, barium, sodium, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from iron, tin, chromium, cobalt, nickel, barium, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from calcium, potassium, magnesium, zinc, aluminum, manganese, chromium, cobalt, nickel, barium, sodium, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from aluminum, calcium, potassium, sodium, magnesium, manganese, zinc, or a combination or mixture thereof. In some embodiments, the composition comprises a metal cation selected from calcium, magnesium, manganese, zinc, or a combination or mixture thereof. In some embodiments, the composition comprises a divalent metal cation. In some embodiments, the composition comprises a divalent metal cation selected from Ca2+, Mg2+, Zn2+, Mn2+, or a combination or mixture thereof. In some embodiments, the composition comprises Mg2+. In some embodiments, the composition comprises Ca2+. In some embodiments, the composition comprises Zn2+. In some embodiments, the composition comprises aluminum. Moreover, the metal cation can be added to the composition in any suitable form, for example any pharmaceutically acceptable salt with any appropriate counterion. Suitable metal salts include, for example, calcium chloride, calcium carbonate, calcium acetate, magnesium chloride, magnesium acetate, zinc acetate, zinc chloride, or mixtures thereof. In some embodiments, the composition comprises calcium chloride, magnesium chloride, zinc acetate, or any combination or mixture thereof. In some embodiments, the composition comprises calcium chloride. In some embodiments, the composition comprises magnesium chloride. In some embodiments, the composition comprises zinc acetate.
- Suitable organic cations include, for example, ammonium hydroxide. D-arginine, L-arginine, t-butylamine, calcium acetate hydrate, calcium carbonate, calcium DL-malate, calcium hydroxide, choline, ethanolamine, ethylenediamine, glycine. L-histidine, L-lysine, magnesium hydroxide, N-methyl-D-glucamine, L-ornithine hydrochloride, potassium hydroxide, procaine hydrochloride. L-proline, pyridoxine. L-serine, sodium hydroxide, DL-triptophan, tromethamine, L-tyrosine, L-valine, carnitine, taurine, creatine malate, arginine alpha keto glutarate, ornithine alpha keto glutarate, spermine acetate, spermidine chloride, or combinations or mixtures thereof. In some embodiments, the organic cation is selected from the group consisting of N-methyl D-glucamine, choline, arginine, lysine, procaine, tromethamine (TRIS), spermine, N-methyl-morpholine, glucosamine, N,N-bis 2-hydroxyethyl glycine, diazabicycloundecene, creatine, arginine ethyl ester, amantadine, rimantadine, ornithine, taurine, citrulline, or a combination or mixture thereof.
- The composition can comprise any stabilizing amount of a cation. For example, the composition can comprise a molar ratio of cation to linaclotide between 100:1 and 1:100. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 1:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 90:1 and 2:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 80:1 and 5:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 70:1 and 10:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 60:1 and 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 50:1 and 30:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 40:1 and 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 25:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 30:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 50:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 60:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 100:1 and 70:1.
- In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 5:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 10:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 20:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 25:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 30:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 40:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide of at least 60:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 5:1 and 1:1. In some embodiments, the composition comprises a molar ratio of cation to linaclotide between 1:100 and 1:1.
- In some embodiments, the composition comprises about 0.5 to about 5% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 4% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 2% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 1.5% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 1.25% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.5 to about 1% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.6 to about 1.5% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.6 to about 1.25% by weight of the cation or salt thereof. In some embodiments, the composition comprises about 0.6 to about 1% by weight of the cation or salt thereof.
- In some embodiments, the composition comprises two or more stabilizing agents. For example, the composition can include a stabilizing amount of a polymer and a stabilizing amount of a sterically hindered primary amine. Moreover, the composition can include a stabilizing amount of a polymer and a stabilizing amount of a cation (e.g., metal cation). In addition, the composition can include a stabilizing amount of a sterically hindered primary amine and a stabilizing amount of a cation (e.g., metal cation). In some embodiments, the composition comprises a stabilizing amount of a polymer, a stabilizing amount of a sterically hindered primary amine, and a stabilizing amount of a cation.
- In some embodiments, the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVP and a stabilizing amount (e.g. a molar ratio of amino acid to linaclotide between 100:1 and 30:1 or between 60:1 and 30:1) of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of leucine, isoleucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of leucine. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of arginine, cysteine, glycine, lysine, proline, serine, or a mixture thereof.
- In some embodiments, the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVA and a stabilizing amount (e.g., a molar ratio of amino acid to linaclotide between 100:1 and 30:1 or between 60:1 and 30:1) of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of an amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, typtophan, tyrosine, valine, or a mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of leucine, isoleucine, methionine, alanine, or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of leucine. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of arginine, cysteine, glycine, lysine, proline, serine, or a mixture thereof.
- In some embodiments, the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVP and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation). In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of a divalent metal cation. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Mg2+, Ca2+, Zn2+ or a salt thereof or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Ca2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Mg2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP and a stabilizing amount of Zn2+ or a salt thereof.
- In some embodiments, the composition comprises a stabilizing amount (e.g., about 0.1-0.5 wt. %) of PVP and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- In some embodiments, the composition comprises a stabilizing amount (e.g., about 0.1-2.5 wt. %) of PVA and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation). In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of a divalent metal cation. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Mg2+, Ca2+, Zn2+ or a salt thereof or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Ca2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Mg2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA and a stabilizing amount of Zn2+ or a salt thereof.
- In some embodiments, the composition comprises a stabilizing amount (e.g., about 0.1-0.5 wt. %) of PVA and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a cation (e.g., metal cation).
- In some embodiments, the composition comprises a stabilizing amount (e.g., a molar ratio of amino acid to linaclotide between 100:1 and 30:1, between 60:1 and 30:1, or even between 50:1 and 30:1) of an amino acid selected from leucine, isoleucine, methionine, alanine; and a stabilizing amount (e.g., a molar ratio of cation to linaclotide between 100:1 and 30:1 or between 100:1 and 60:1) of a divalent metal cation selected from Mg2+, Ca2+, Zn2+ or a salt thereof or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of an amino acid selected from leucine, isoleucine; and a stabilizing amount of a divalent metal cation selected from Mg2+, Ca2+ or a salt thereof or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of an amino acid selected from leucine or methionine; and a stabilizing amount of a divalent metal cation selected from Ca2+, Zn2+ or a salt thereof or a combination or mixture thereof.
- In some embodiments, the composition comprises a stabilizing amount of leucine and a stabilizing amount of Ca2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of a cation and a stabilizing amount of a sterically hindered primary amine. In some embodiments, the composition comprises a cation and a sterically hindered primary amine in a molar ratio of cation:sterically hindered primary amine (e.g., Ca2+:leucine) of at least 1.5:1, e.g., at least 2:1, at least 2.5:1, at least 3:1, at least 4:1, or even at least 5:1 (for example, a molar ratio between 1.5:1 and 5:1, e.g., between 2:1 and 4:1, and between 1.5:1 and 2:1).
- In some embodiments, the composition comprises (i) a stabilizing amount of PVP or PVA, (ii) a stabilizing amount of leucine, isoleucine, methionine, alanine, and (iii) a stabilizing amount of Mg2+, Ca2+, Zn2+ or a salt thereof or a combination or mixture thereof. In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of a metal cation. In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Ca2+ or a salt thereof.
- In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Mg2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVP, a stabilizing amount of leucine, and a stabilizing amount of Zn2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Ca2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Mg2+ or a salt thereof. In some embodiments, the composition comprises a stabilizing amount of PVA, a stabilizing amount of leucine, and a stabilizing amount of Zn2+ or a salt thereof.
- In some embodiments, the composition comprises (i) between 0.01 and 5 wt. % of a polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide between 100:1 and 10:1, and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises (i) between 0.1 and 3 wt. % of a polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide 100:1 and 30:1 (e.g., between 60:1 and 30:1 or even between 50:1 and 30:1), and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide between 100:1 and 60:1.
- In some embodiments, the composition comprises (i) between 0.01 and 5 wt. % of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide between 100:1 and 10:1, and (iii) a metal cation selected from Ca2+, Mg2+, and Zn2+ in a molar ratio of cation to linaclotide between 100:1 and 40:1.
- In some embodiments, the composition comprises (i) between 0.1 and 3 wt. % of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide 100:1 and 30:1 (e.g., between 60:1 and 30:1), and (iii) a metal cation selected from Ca2+, Mg2+, and Zn2+ in a molar ratio of cation to linaclotide between 100:1 and 60:1. In some embodiments, the composition comprises (i) between 0.01 and 5 wt. % (e.g., between 0.1 and 3 wt. % or even between 0.1 and 2.5 wt. %) of PVP or PVA, (ii) leucine in a molar ratio of leucine to linaclotide between 100:1 and 30:1 (e.g., between 60:1 and 30:1 or even between 50:1 and 30:1), and (iii) Ca2+ in a molar ratio of Ca2+ to linaclotide between 100:1 and 60:1.
- In some embodiments, the composition comprises (i) between 0.01 and 5 wt. % (e.g., between 0.1 and 3 wt. % or even between 0.1 and 2.5 wt. %) of PVP, PVA or HPMC, (ii) leucine in a molar ratio of leucine to linaclotide between 60:1 and 10:1 (e.g., between 50:1 and 10:1 or even between 40:1 and 20:1), and (iii) Ca2+ (or salt thereof) in a molar ratio of Ca2+ (or salt thereof) to linaclotide between 100:1 and 40:1 (e.g., between 80:1 and 40:1 or between 70:1 and 50:1). In some embodiments, the composition comprises (i) between 0.01 and 5 wt. % (e.g., between 0.1 and 3 wt. % or even between 0.1 and 2.5 wt. %) of HPMC, (ii) leucine in a molar ratio of leucine to linaclotide between 60:1 and 10:1 (e.g., between 50:1 and 10:1 or even between 40:1 and 20:1), and (iii) Ca2+ (or salt thereof) in a molar ratio of Ca2+(or salt thereof) to linaclotide between 100:1 and 40:1 (e.g., between 80:1 and 40:1 or between 70:1 and 50:1).
- In some embodiments, the composition comprises (i) between 0.01 and 0.5 wt. % of a polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide between 100:1 and 10:1, and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises (i) between 0.01 and 5 wt. % of a polymer, (ii) a sterically hindered primary amine (e.g., an amino acid) in a molar ratio of primary amine to linaclotide between 100:1 and 50:1, and (iii) a cation (e.g., a metal cation) in a molar ratio of cation to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises (i) between 0.01 and 0.5 wt. % of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide between 100:1 and 10:1, and (iii) a metal cation selected from Ca2+, Mg2+, and Zn2+ in a molar ratio of cation to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises (i) between 0.01 and 5 wt. % of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide between 100:1 and 50:1, and (iii) a metal cation selected from Ca2+, Mg2+, and Zn2+ in a molar ratio of cation to linaclotide between 100:1 and 40:1.
- In some embodiments, the composition comprises linaclotide (e.g., between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide), Ca2+or a salt thereof in a concentration between 1.2 and 1.8% by weight, leucine in a concentration between 0.5 and 0.9% by weight, and optionally between 0.5 and 0.9% by weight (e.g., between 0.6 and 0.75% by weight) of HPMC. In some embodiments, the composition comprises linaclotide (e.g., between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide), Ca2+ or a salt thereof in a concentration between 1.4 and 1.65% by weight, leucine in a concentration between 0.5 and 0.8% by weight, and optionally between 0.5 and 0.9% by weight (e.g., between 0.6 and 0.75% by weight) of HPMC. In some embodiments, the composition comprises linaclotide (e.g. between 0.1 and 1% by weight, between 0.1 and 0.5% by weight or between 0.2 and 0.4% by weight of linaclotide), Ca or a salt thereof in a concentration between 1.45 and 1.65% by weight, leucine in a concentration between 0.6 and 0.75% by weight, and optionally between 0.5 and 0.9% by weight (e.g., between 0.6 and 0.75% by weight) of HPMC.
- In some embodiments, the pharmaceutical composition comprises linaclotide, leucine in a molar ratio of leucine to linaclotide between 70:1 and 10:1 and Ca2+ or a salt thereof in a molar ratio of Ca2+ or a salt thereof to linaclotide between 100:1 and 30:1. In further embodiments, the composition comprises a molar ratio of Ca2+ or a salt thereof to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises a molar ratio of leucine to linaclotide between 60:1 and 20:1 and a molar ratio of Ca2+ or a salt thereof to linaclotide between 100:1 and 40:1. In some embodiments, the composition comprises a molar ratio of leucine to linaclotide between 40:1 and 20:1. In some embodiments, the composition comprises a molar ratio of leucine to linaclotide between 40:1 and 20:1. In some embodiments, the composition comprises a molar ratio of Ca2+ or a salt thereof to leucine between 1.5:1 and 5:1. In still further embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering a use environment. In some further embodiments, the composition comprises between 100 μg and 300 μg of linaclotide. In some embodiments, the composition comprises about 266 μg of linaclotide. In some embodiments, the composition comprises about 133 μg of linaclotide. In some embodiments, the composition further comprises hydroxypropyl methyl cellulose. In some embodiments, the composition is a capsule. In some embodiments, the composition is a tablet.
- In some embodiments, the pharmaceutical composition comprises linaclotide, leucine in a molar ratio of leucine to linaclotide between 70:1 and 10:1, and Ca2+ or a salt thereof in a molar ratio of Ca2+ or a salt thereof to leucine between 1.5:1 and 5:1. In further embodiments, the composition comprises leucine in a molar ratio to linaclotide between 50:1 and 10:1. In some embodiments, the composition comprises leucine in molar ratio to linaclotide between 40:1 and 20:1.
- The composition may also comprise any suitable pharmaceutically acceptable carrier or medium. Suitable pharmaceutically acceptable carriers include, for example, any solvents, dispersants, pH buffering agents, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients (e.g., filling agents, starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, disintegrating agents), or the like. In addition, the compositions can contain any desired additional components, additives, and/or species, for example, surface active additives, dispersing additives, humectants, suspending agents, solubilizers, buffering agents, disintegrants, preservatives, colorants, flavorants, and the like. In some embodiments, the composition comprises one or more ion species that interact with linaclotide.
- The composition can also comprise any suitable pH buffering agent. In some embodiments, the pH buffering agent is present in the composition in an amount sufficient to achieve the isoelectric point of linaclotide. In some embodiments, the composition can have any desired pH. In some embodiments, the composition has a pH of 2 to 5 (for example, a pH of 2 to 4.5, a pH of 2 to 4, a pH of 2.5 to 4, a pH of 2.5 to 3.5, a pH1 of 2.5 to 3, or even a pH of 3).
- The composition may also comprise any one or more filling agents. Suitable filling agents include, but are not limited to starch, calcium carbonate, calcium sulfate, hydroxylpropylmethyl cellulose, fructose, methyl cellulose, dextrates, dextrose, lactitol, maltose, sucrose, sorbitol, isomalt, pregelatinized starch, dicalcium phosphate, microcrystalline cellulose, mannitol, gelatin, trehalose, erythitol, maltitol, lactose, glucose, or a combination thereof, or a mixture thereof. In some embodiments, the filling agent is isomalt. In some embodiments, the filling agent is gelatin. In some embodiments, the tilling agent is mannitol. In some embodiments, the filling agent is pregelatinized starch. In some embodiments, the filling agent is microcrystalline cellulose. In some embodiments, the composition comprises a tablet filler and a granule filler.
- The composition can comprise any suitable concentration of filling agent. In some embodiments, for example, the composition comprises one or more filling agents in a concentration of 0.1-95% by weight, relative to the total weight of the composition. In some embodiments, for example, the composition comprises one or more filling agents in a concentration of 1-90 wt. % of filling agent(s), relative to the total weight of the composition. In some embodiments, for example, the composition comprises one or more filling agents in a concentration of 10-90 wt. % of filling agent(s), relative to the total weight of the composition. In some embodiments, for example, the composition comprises one or more filling agents in a concentration of 20-90 wt. % of filling agent(s), relative to the total weight of the composition. In some embodiments, for example, the composition comprises one or more filling agents in a concentration of 30-80 wt. % of filling agent(s), relative to the total weight of the composition, in some embodiments, the composition comprises one or more filling agents in a concentration of at least wt. %, for example, at least 40 wt. %, at least 60 wt. %, or at least 80 wt. %, relative to the total weight of the composition.
- Suitable disintegrants include, for example, agar-agar, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, povidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, clays, other algins, other celluloses, gums, and mixtures thereof. In some embodiments, the disintegrant is crospovidone. In some embodiments, the disintegrant is croscarmellose sodium.
- Suitable lubricants include, for example, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil), zinc stearate, ethyl oleate, ethyl laurate, agar, syloid silica gel (AEROSIL 200, W.R. Grace Co., Baltimore, Md. USA), a coagulated aerosol of synthetic silica (Evonik Degussa Co. Plano, Tex. USA), a pyrogenic silicon dioxide (CAB-O-SIL, Cabot Co., Boston, Mass. USA), and mixtures thereof.
- Suitable anti-caking additives include, for example, calcium silicate, magnesium silicate, silicon dioxide, colloidal silicon dioxide, talc, and mixtures thereof.
- Suitable anti-microbial additives that may be used, e.g., as a preservative for the linaclotide compositions, include, for example, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, butyl paraben, cetylpyridinium chloride, cresol, chlorobutanol, dehydroacetic acid, ethylparaben, methylparaben, phenol, phenylethyl alcohol, phenoxyethanol phenylmercuric acetate, phenylmercuric nitrate, potassium sorbate, propylparaben, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimersol, thymo, and mixtures thereof.
- Suitable coating additives include, for example, sodium carboxymethyl cellulose, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methyl cellulose phthalate, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, and mixtures thereof. In some embodiments, coating additives are selected from sodium carboxymethyl cellulose, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcrystalline wax, and mixtures thereof. In certain embodiments, suitable additives for the linaclotide composition include one or more of sucrose, talc, magnesium stearate, crospovidone or BHA. In certain embodiments, suitable coating additives for the linaclotide composition include one or more of magnesium stearate, crospovidone or BHA.
- In some embodiments, the composition comprises linaclotide and a hydrolysis product, e.g., a hydrolysis product comprising or having a structure of:
- The composition can contain any desired concentration of the hydrolysis product. In some embodiments, the composition comprises less than 10 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 7 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 6 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 4 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises less than 1 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.01 and 10 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 7 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.05 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 4 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 4 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 4 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 3 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 2.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.05 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 1 and 2 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the hydrolysis product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the hydrolysis product.
- In some embodiments, the composition comprises linaclotide and a formaldehyde imine product, e.g., a formaldehyde imine product comprising or having a structure of:
- The composition can contain any desired concentration of the formaldehyde imine product. In some embodiments, the composition comprises less than 10 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 7 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 6 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 3 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises less than 1 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.01 and 10 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 7 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.05 and 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 4 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 3 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 3 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 2.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.05 and 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 1 and 2 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the formaldehyde imine product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the formaldehyde imine product.
- In some embodiments, the composition comprises linaclotide and an oxidation product, e.g., an oxidation product comprising or having a structure of:
- Alternatively, or in addition, the composition comprises linaclotide and an oxidation product having the depicted structure but wherein oxidation occurs at any one or more of the six depicted cysteinyl sulfurs. The composition can contain any desired concentration of the oxidation product. In some embodiments, the composition comprises less than 10 wt. % of the oxidation product. In some embodiments, the composition comprises less than 7 wt. % of the oxidation product. In some embodiments, the composition comprises less than 6 wt. % of the oxidation product. In some embodiments, the composition comprises less than 5 wt. % of the oxidation product. In some embodiments, the composition comprises less than 4 wt. % of the oxidation product. In some embodiments, the composition comprises less than 3 wt. % of the oxidation product. In some embodiments, the composition comprises less than 2 wt. % of the oxidation product. In some embodiments, the composition comprises less than 1 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.01 and 10 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.01 and 7 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.01 and 5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.05 and 5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 5 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 4 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 4 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 4 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 3 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 3 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 2.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.05 and 2 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the oxidation product. In some embodiments, the composition comprises between 1 and 2 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the oxidation product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the oxidation product.
- In some embodiments, the composition comprises linaclotide and an acetylation product, e.g., an acetylation product comprising or having:
- The composition can contain any desired concentration of the acetylation product. In some embodiments, the composition comprises less than 10 wt. % of the acetylation product. In some embodiments, the composition comprises less than 7 wt. % of the acetylation product. In some embodiments, the composition comprises less than 6 wt. % of the acetylation product. In some embodiments, the composition comprises less than 5 wt. % of the acetylation product. In some embodiments, the composition comprises less than 4 wt. % of the acetylation product. In some embodiments, the composition comprises less than 3 wt. % of the acetylation product. In some embodiments, the composition comprises less than 2 wt. % of the acetylation product. In some embodiments, the composition comprises less than 1 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.01 and 10 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 7 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 5 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 4 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 4 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 4 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 3 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 3 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 3 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 2.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 2 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 2 wt. % of the acetylation product. In some embodiments, the composition comprises between 1 and 2 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.1 and 1 wt. % of the acetylation product. In some embodiments, the composition comprises between 0.5 and 1 wt. % of the acetylation product.
- In some embodiments, the composition comprises linaclotide and any desired concentration of multimers. In some embodiments, the composition comprises less than 10 wt. % of multimer(s). In some embodiments, the composition comprises less than 7 wt. % of multimer(s). In some embodiments, the composition comprises less than 6 wt. % of multimer(s). In some embodiments, the composition comprises less than 5 wt. % of multimer(s). In some embodiments, the composition comprises less than 4 wt. % of multimer(s). In some embodiments, the composition comprises less than 3 wt. % of multimer(s). In some embodiments, the composition comprises less than 2 wt. % of multimer(s). In some embodiments, the composition comprises less than 1 wt. % of multimer(s). In some embodiments, the composition comprises between 0.01 and 10 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 7 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 5 wt. % of multimer(s). In some embodiments, the composition comprises between 1 and 5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 4 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 4 wt. % of multimer(s). In some embodiments, the composition comprises between 1 and 4 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 3 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 3 wt. % of multimer(s). In some embodiments, the composition comprises between 1 and 3 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 2.5 wt. %, of multimer(s). In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of multimer(s). In some embodiments, the composition comprises between 1 and 2.5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 2 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 2 wt. % of multimer(s). In % some embodiments, the composition comprises between 1 and 2 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of multimer(s). In some embodiments, the composition comprises between 0.1 and 1 wt. % of multimer(s), in some embodiments, the composition comprises between 0.5 and 1 wt. % of multimer(s).
- In some embodiments, the composition comprises an effective amount of linaclotide and any desired amount of reduced form linaclotide. As used herein, the term “reduced form linaclotide” refers to linaclotide having no disulfide bonds between cysteine amino acids. In some embodiments, the composition comprises less than 10 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 7 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 6 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 4 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 3 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 2 wt. % of reduced form linaclotide. In some embodiments, the composition comprises less than 1 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.01 and 10 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 7 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 4 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 4 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 4 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 3 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 3 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 3 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 2.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 2 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 2 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 1 and 2 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.1 and 1 wt. % of reduced form linaclotide. In some embodiments, the composition comprises between 0.5 and 1 wt. % of reduced form linaclotide.
- In some embodiments, the composition comprises an effective amount of linaclotide and any desired amount of scrambled form linaclotide. As used herein, the term “scrambled form linaclotide” refers to linaclotide having disulfide bonds between Cys1 and Cys10, between Cys1 and Cys13, between Cys1 and Cys5, between Cys1 and Cys2, between Cys2 and Cys6, between Cys2 and Cys13, between Cys2 and Cys5, between Cys5 and Cys6, and/or between Cys5 and Cys10. In some embodiments, the composition comprises less than 10 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 7 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 6 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 4 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises less than 1 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.01 and 10 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 7 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 4 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 4 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 4 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 3 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 2.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 2.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 2.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 1 and 2 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 1.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 1.5 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.1 and 1 wt. % of scrambled form linaclotide. In some embodiments, the composition comprises between 0.5 and 1 wt. % of scrambled form linaclotide.
- In some embodiments, the composition comprises a total degradant concentration of less than about 10 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 8 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 7 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 6.5 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 6 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 5.5 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 5 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 4 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 3 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 2.5 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 2 wt. %. In some embodiments, the composition comprises a total degradant concentration of less than about 1 wt. %.
- The composition can comprise any effective amount of linaclotide. In some embodiments, for example, the composition comprises from 0.05 g to 6 mg of linaclotide. In some embodiments, for example, the composition comprises from 0.1 μg to 6 mg of linaclotide. In some embodiments, for example, the composition comprises from 25 μg to 6 mg of linaclotide. In some embodiments, the composition comprises from 25 μg to 2 mg of linaclotide, for example, from 50 μg to 1 mg of linaclotide. In some embodiments, the composition comprises from 50 μg to 2 mg of linaclotide. In some embodiments, for example, the composition comprises from 0.1 μg to 90 μg of linaclotide. In some embodiments, for example, the composition comprises from 0.1 μg to 45 μg of linaclotide. In some embodiments, for example, the composition comprises from 0.1 μg to 25 μg of linaclotide. In some embodiments, the composition comprises 0.05 μg, 0.1 μg, 0.25 μg, 0.5 μg, 0.75 μg, 1 μg, 1.5 μg, 2 μg, 2.5 μg, 3 μg, 3.5 μg, 4 μg, 4.5 μg, 5 μg, 7.5 μg, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 60 μg, 75 μg, 90 μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg or 1 mg of linaclotide. In some embodiments, the composition comprises from 100 μg to 600 μg of linaclotide. In some embodiments, the composition comprises 50 μg, 100 μg, 150 μg, 200 μg, 300 μg, 400 μg, 500 μg or 600 μg of linaclotide. In some embodiments, the composition comprises 75 μg, 150 μg, 300 μg, or 600 μg of linaclotide.
- In some embodiments, the composition comprises 75 μg of linaclotide. In some embodiments, the composition comprises about 133 μg of linaclotide. In some embodiments, the composition comprises 150 μg of linaclotide. In some embodiments, the composition comprises about 266 μg of linaclotide. In some embodiments, the composition comprises 300 μg of linaclotide. In some embodiments, the composition comprises 600 μg of linaclotide. In some embodiments, the composition comprises 0.1 μg, 0.25 μg, 0.5 μg, or 0.75 μg of linaclotide. In some embodiments, the composition comprises 0.1 μg of linaclotide. In some embodiments, the composition comprises 0.25 μg of linaclotide. In some embodiments, the composition comprises 0.5 μg of linaclotide. In some embodiments, for example, the composition comprises from 0.05 μg to 25 μg of linaclotide.
- The composition can be in any desired form, such as, for example, any desired solid form for oral administration. Examples of suitable solid dosage forms include, without limitation, tablets, capsules, gelcaps, sachets, pellets, caplets, granules, lozenges and bulk powders. In some embodiments, the composition can be in the form selected from pellets, caplets, granules, lozenges and bulk powders.
- In some embodiments, the composition is an immediate release composition (for example, an immediate release tablet or an immediate release capsule). The immediate release composition can have any desired dissolution rate. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering a use environment. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering a use environment. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering a use environment. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering a use environment. In some embodiments, the composition releases at least 50% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering a use environment. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering a use environment.
- In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution (e.g., phosphate buffer solution) having a pH of 4.5. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 50% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 4.5. The buffer solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 50% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 60% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within IS minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 50% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 60% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 70% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 5 minutes of entering an agitated solution of 0.1 N HCl. The solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated buffer solution having a pH of 6.8. The buffer solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 30 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 80% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 85% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 90% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. In some embodiments, the composition releases at least 95% of the linaclotide contained therein within 15 minutes of entering an agitated solution of simulated intestinal fluid without enzymes. The solution can be agitated using USP Apparatus II (Paddle) at 50 rpm, a USP Apparatus I at 100 rpm, or the like.
- The compositions may be prepared in any suitable manner, such as described, for example, in the Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (current edition): Pharmaceutical Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors) current edition, published by Marcel Dekker, Inc. as well as Remington's Pharmaceutical Sciences (Arthur Osol, editor), 1553-1593 (current edition). For example, the compositions can be prepared using a method comprising: (a) providing a solution, e.g. an aqueous solution comprising linaclotide, or a pharmaceutically acceptable salt thereof, and stabilizing amount(s) of polymer, sterically hindered primary amine and/or cation component(s) and optionally other excipients; (h) applying the aqueous solution to a pharmaceutically acceptable filler to generate linaclotide-coated tiller (e.g. by spraying, mixing or coating the pharmaceutically acceptable filler with the coating solution); and optionally (c) compressing the linaclotide-coated filler into tablets. The method can optionally include one or more of: (i) blending the linaclotide-coated tiller with a pharmaceutically acceptable glidant, a pharmaceutically acceptable lubricant, or a pharmaceutically acceptable additive that acts as both a glidant and lubricant; (ii) blending the linaclotide-coated filler with tiller that is not linaclotide-coated, (iii) blending the linaclotide-coated filler with other additives; (iv) applying a pharmaceutically acceptable coating additive to the linaclotide-coated filler; and optionally (v) compressing the linaclotide-coated filler into tablets. The final pharmaceutical composition can be placed into any suitable formulation, such as capsules (e.g. gelatin capsules) or tablets.
- The composition can also be used to treat diseases, disorders, or conditions that are responsive to treatment with agonists of the GC-(C receptor. The composition can be used to treat any gastrointestinal disorders and/or conditions in a patient (e.g. mammal or human) or inflammation or pain associated therewith. Suitable such gastrointestinal disorders and conditions, include, but are not limited to, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, dyspepsia (including functional dyspepsia or non-ulcer dyspepsia), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, for example, chronic constipation, opioid induced constipation, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders or a combination of symptoms thereof (such as a combination of irritable bowel syndrome and chronic constipation). In some embodiments, a method is provided for treating gastrointestinal disorders in a patient (e.g., mammal or human) diagnosed with one or more gastrointestinal disorders or conditions, wherein the method comprises administering an effective amount of the composition to the patient.
- In another embodiment, a method is provided for increasing intestinal motility in a patient in need thereof, comprising administering an effective amount of the composition to the patient. Intestinal motility involves spontaneous coordinated dissentions and contractions of the stomach, intestines, colon and rectum to move food through the gastrointestinal tract during the digestive process.
- In exemplary embodiments, the methods may comprise administering a therapeutically effective amount of the pharmaceutical composition to a patient in need thereof.
- An effective amount of a composition comprising linaclotide or a pharmaceutically acceptable salt thereof required to achieve desired results (such as desired treatment and/or symptom relief) of a subject is dependent on several understood factors, such as the identity and severity of the disorder being treated, as well as the age, weight, etc. of the patient being treated.
- A subject or patient in whom administration of the pharmaceutical composition is an effective therapeutic regimen for a disease or disorder is preferably a human, but can be any animal, including a laboratory animal in the context of a clinical trial or screening or activity experiment. Thus, as can be readily appreciated by one of ordinary skill in the art, the methods, compounds and compositions described herein are particularly suited for administration to any animal, particularly a mammal, and including, but by no means limited to, humans, rodents and non-rodents, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, wild animals (whether in the wild or in a zoological garden), research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats. etc. avian species, such as chickens, turkeys, songbirds, etc., e.g., for veterinary medical use.
- In some embodiments, the effective dose range of linaclotide for adult humans is from 25 μg to 6 mg per day orally. In some embodiments, the dose range is 25 μg to 2 mg per day orally. In some embodiments, the dose range for adult humans is 50 μg to 1 mg per day orally (e.g., 50 μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg or 1 mg). In some embodiments, the dose range is 100 μg to 600 μg per day orally. In some embodiments, the dose is 50 μg, 100 μg, 150 μg, 200 μg, 300 μg, 400 μg, 500 μg or 600 μg linaclotide per day orally. In some embodiments, the dose is 50 μg linaclotide per day orally. In some embodiments, the dose is 100 μg linaclotide per day orally. In some embodiments, the dose is 150 μg linaclotide per day orally. In some embodiments, the dose is 200 μg linaclotide per day orally. In some embodiments, the dose is 300 μg linaclotide per day orally. In some embodiments, the dose is 400 μg linaclotide per day orally. In some embodiments, the dose is 500 μg linaclotide per day orally. In some embodiments, the dose is 600 μg linaclotide per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.05 μg to 2 mg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.05 μg to 100 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 μg to 90 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 μg to 50 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 μg to 15 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 μg to 10 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 μg to 5 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 μg to 1 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is from 0.1 μg to 0.5 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.1 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.25 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 0.5 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 3.5 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 15 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 45 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 60 μg per day orally. In some embodiments, the effective pediatric dose range of linaclotide is 90 μg per day orally. In some embodiments, the unit dosage form and daily dose are equivalent. In some embodiments, the unit dosage form is administered with food at anytime of the day, without food at anytime of the day, with food after an overnight fast (e.g., with breakfast). In some embodiments, the unit dosage form is administered once a day, twice a day or three times a day. In some embodiments, one, two or three unit dosage forms will contain the daily oral dose of linaclotide. The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity.
- In some embodiments, the compositions are administered as a monotherapy. In some embodiments, the composition consists essentially of an effective amount of linaclotide. In some embodiments, the composition consists of an effective amount of linaclotide.
- In other embodiments, the compositions are administered as part of a combination therapy. For example, a composition may be used in combination with other drugs or therapies that are used in the treatment, prevention, suppression, and/or amelioration of the diseases or conditions for which compounds of the invention are useful. The linaclotide can be co-administered or co-formulated with other medications. In one embodiment, the linaclotide composition can be co-administered with other medications used to treat gastrointestinal disorders including but not limited to acid suppressing agents such as Histamine-2 receptor agonists (H2As) and/or proton pump inhibitors (PPIs).
- Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of the invention. When a compound of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical unit dosage form containing such other drugs in addition to the compound of the invention may be employed. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active components, in addition to a compound of invention.
- Several methods can be used for evaluating the bioactivity of the linaclotide composition, including, but not limited to, immunoassays (e.g., enzyme-linked immunosorbent assay), radioimmuno assays, immunoradiometric assays, gel electrophoresis (e.g., SDS-PAGE), high performance liquid chromatography (HPLC), and/or high performance capillary electrophoresis (HPCE). In some embodiments, the bioactivity of the composition is assessed by a method comprising fixing linaclotide, incubating linaclotide with guanylate cyclase C (GCC), incubating GCC bound linaclotide with antibodies against GCC, incubating GCC antibody-bound linaclotide with fluorescently labeled antibodies against GCC antibodies, and detecting the linaclotide bound to the GCC antibodies by measuring the fluorescence intensity using a plate reader. The drug concentration can then be calculated based on the fluorescence reading of the solution.
- For example, the bioactivity of the linaclotide compositions can be assessed and quantified using the following method, though other methods are available. The composition is added to a volumetric flask containing 60 ml of phosphate buffer having a pH of 4.5, and the flask is shaken for 60 minutes. 0.2 ml of the supernatant is then removed, and is added into one or more wells of a 96-well plate that is coated with GCC. The plate is sealed and incubated at 37° C. for 2 hr. At the end of incubation, the sample is removed and the plate is washed with phosphate buffered saline (PBS). The bound linaclotide is then incubated for 1 hour, at room temperature, with GCC (such as is available from Sigma-Aldrich Inc.) labeled with fluorescein isocyanate (FITC) in blocking buffer. After incubation, the well is washed with PBS. The fluorescence intensity of the end product is detected, for example, by using a plate reader. The linaclotide concentration is then calculated based on the fluorescence reading of the solution.
- As used herein, unless otherwise indicated, “linaclotide” refers to a peptide that consists of the amino acid sequence Cys1 Cys2 Glu3 Tyr4 Cys5 Cys6 Asn7 Pro8 Ala9 Cys10 Thr11 Gly12 Cys13 Tyr14 (“linaclotide”, SEQ ID NO: 1), as well as any pharmaceutically acceptable salts or hydrates thereof, any isolated and purified forms thereof, or disulfide forms thereof. “Disulfide forms” of linaclotide are defined herein as linaclotide having one, two, or three of the following disulfide bonds between cysteinyl amino acids: a disulfide bond between Cys1 and Cys6, a disulfide bond between Cys2 and Cys10, and/or a disulfide bond between Cys5 and Cys13. For example, disulfide forms of linaclotide can comprise disulfide bonds between Cys1 and Cys6 and between Cys2 and Cys10. In addition, disulfide forms of linaclotide can comprise disulfide bonds between Cys1 and Cys6 and between Cys5 and Cys13. Moreover, disulfide forms of linaclotide can comprise disulfide bonds between Cys2 and Cys10 and between Cys5 and Cys13.
- As used herein, unless otherwise indicated, the term “isolated and purified” means at least 95 percent pure (for example, at least 96% pure, at least 97% pure, at least 98% pure, or even at least 99% pure), as measured, for example, by chromatographic purity using HPLC.
- The term “released from”, when referring to the release of linaclotide from the composition, unless otherwise indicated, is used herein to mean that the linaclotide no longer remains in a composition form.
- As used herein, unless otherwise indicated, “stabilizing agent” refers to a polymer, sterically hindered primary amine (e.g., amino acid), or cation (e.g., metal cation) component of the composition which is included in the composition in a stabilizing amount. For example, a polymeric stabilizing agent is a polymer that is included in the composition in a stabilizing amount. Similarly, a sterically hindered primary amine stabilizing agent is a sterically hindered primary amine that is included in the composition in a stabilizing amount. Moreover, a cationic stabilizing agent is a cation that is included in the composition in a stabilizing amount.
- As used herein, unless otherwise indicated, “stabilizing amount” refers to a concentration, within the composition, of a polymer, sterically hindered primary amine (e.g., amino acid), or cation component at which the component increases the stability of linaclotide in the composition, as compared to a similar composition not having a stabilizing amount of the same component.
- As used herein, unless otherwise indicated, the term “entry into a use environment” means contact of the composition with saliva, gastric fluids, or enteric fluids of the patient to whom it is administered, or with a fluid intended to simulate saliva, gastric fluid, or enteric fluid for example an agitated buffer solution have a pH of 4.5, an agitated 0.1 N HCl solution, an agitated buffer solution having a pH of 6.8, or an agitated solution of simulated intestinal fluid without enzymes.
- As used herein, unless otherwise indicated, the term “agitated”, when used to refer to a solution means that the solution is agitated using USP Apparatus II at 50 rpm. USP Apparatus I at 100 rpm, or the like.
- As used herein, unless otherwise indicated, “therapeutically effective amount” means the amount of a linaclotide or a pharmaceutically acceptable salt thereof that, when administered to a mammal for treating a state, disorder or condition, is sufficient to effect a treatment (as defined below). The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, sex, weight, physical condition and responsiveness of the mammal to be treated. For example, a therapeutically effective amount of linaclotide, or its pharmaceutically acceptable salt or hydrate, can be an amount effective to treat gastrointestinal disorders, including irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation and/or dyspepsia.
- As used herein, unless other indicated, “pharmaceutically acceptable” means biologically or pharmacologically compatible for in vive use in animals or humans, and preferably means, approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- As used herein, unless otherwise indicated, the term “treat”, in all its verb forms, is used herein to mean to relieve, alleviate, prevent, and/or manage at least one symptom of a disorder in a subject, the disorder including, for example, a gastrointestinal disorder, such as, irritable bowel syndrome, constipation-predominant irritable bowel syndrome, chronic constipation, opioid induced constipation, dyspepsia, or a combination of symptoms thereof. Within the meaning of the present invention, the term “treat” also denotes, to arrest, delay the onset (i.e., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease. The term “treatment” means the act of “treating” as defined above.
- As used herein, unless otherwise indicated, the term “additives” refers to a pharmaceutically acceptable additive. Pharmaceutically acceptable additives include, without limitation, binders, disintegrants, dispersing additives, lubricants, glidants, antioxidants, coating additives, diluents, surfactants, flavoring additives, humectants, absorption promoting additives, controlled release additives, anti-caking additives, anti-microbial agents (e.g. preservatives), colorants, desiccants, plasticizers and dyes.
- As used herein, unless otherwise indicated, an “excipient” is any pharmaceutically acceptable additive, filler, binder or agent.
- As used herein, unless otherwise indication, “stressed conditions” refer to 40° C. and 75% relative humidity (RH).
- As used here, unless otherwise indicated, the terms “about” and “approximately” mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend, in part, on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per practice in the art. Alternatively, “about” with respect to the compositions can mean plus or minus a range of up to 20%, preferably up to 10%. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Particular values are described in the application and claims, unless otherwise stated the term “about” means within an acceptable error range for the particular value.
- All weight percentages (i.e., “% by weight” and “wt. %” and w/w) referenced herein, unless otherwise indicated, are measured relative to the total weight of the pharmaceutical composition.
- The term “consisting essentially of”, and variants thereof, when used to refer to the composition, are used herein to mean that the composition includes linaclotide and other desired pharmaceutically inactive additives, excipients, and/or components (e.g., polymers, sterically hindered primary amines, cations, filling agents, binders, carriers, excipients, diluents, disintegrating additives, lubricants, solvents, dispersants, coating additives, absorption promoting additives, hydrolysis products, formaldehyde imine products, oxidation products, acetylation products, deamidation products, multimers, controlled release additives, anti-caking additives, anti-microbial additives, preservatives, sweetening additives, colorants, flavors, desiccants, plasticizers, dyes, or the like), and no other active pharmaceutical ingredient(s).
- The following examples are merely illustrative of the present invention and should not be construed as limiting the scope of the invention in any way as many variations and equivalents that are encompassed by the present invention will become apparent to those skilled in the art upon reading the present disclosure.
- The following tests were employed in the examples section, unless otherwise indicated:
- 1) Stability of Linaclotide Compositions.
- For stability evaluation, linaclotide compositions (0.15 mg theoretical, actual 0.135 mg) were packaged into a HDPE bottle with desiccant, and stored under at 40° C./75% RH (“stressed conditions”). The amount of linaclotide was assayed initially and after 3, 6, 9, 12, or 18 months of storage at stressed conditions. The concentration of linaclotide was analyzed and quantified using an HPLC method with the following mobile phase gradient: Mobile phase A: 50 mM of sodium perchlorate in a solvent containing 76% water and 24% acetonitrile and 0.1% of trifluoroacetic acid; Mobile phase B: 50 mM of sodium perchlorate in a solvent containing 5% water and 95% acetonitrile and 0.1% of trifluoroacetic acid; Flow rate: 0.6 ml/min; Column: YMC Pro C 18, 150 mm×3 mm ID, 3 μm or equivalent; Column temperature: 40° C.; Fluorescence detection: excitation: 274 nm; emission: 303 nm; Injection volume: 100 μl.
- 2) Analysis of Total Degradants in the Pharmaceutical Composition:
- Degradant analysis was performed using an HPLC method employing the following conditions: Mobile phase A: Water: acetonitrile 98:2, with 0.1% (v/v) of trifluoroacetic acid; Mobile phase B: Water: acetonitrile 5:95, with 0.1% (v/v) of trifluoroacetic acid; Flow rate: 0.6 ml/min; Column: YMC Pro C18, 150 mm×3 mm ID, 3 μm or equivalent; Column temperature: 40° C.; UV detection: excitation: 220 nm; Injection volume: 50 μl. The percentage amounts of degradants in the composition were calculated by quantifying the area of all peaks in the HPLC chromatogram to obtain the “total peak area”, and dividing the peak area of each degradant by the total peak area.
- 3) Dissolution Test:
- The dissolution performance of the composition was assessed in phosphate buffer, pH 4.5 using USP Apparatus II (Paddle, 50 rpm).
- 1000 g of HCl solution (0.0001N, pH 4) was weighed in a container and PVP (50% of theoretical weight), linaclotide, calcium chloride, and leucine were added into the HCl solution while mixing, until a clear coating solution was obtained. Isomalt and PVP (50% of theoretical weight) were charged into the bowl of the fluid bed (Glatt GCGP 3.1, Glatt, Ramsey N.J.) and mixed for 2 minutes by fluidizing the powder. The coating solution was top sprayed on the fluidized powder at a speed of 10 g/min and the granules were dried for 20 minutes at a product temperature of 40° C. The granules were discharged and sieved through a 20 mesh hand screen. The linaclotide granules, isomalt, and crospovidone were weighed, screened together through a 20 mesh hand screen, charged into a V-blender shell (available from Patterson-Kelly, East Stroudsburg, Pa.), and mixed for 20 minutes. Talc was weighed and screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 minutes. Magnesium stearate was weighed, screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 minutes. The blend was discharged and added into the hopper of a tablet press. The linaclotide tablets were compressed with a weight of 200 mg and hardness of 4-6 kp. The composition of resulting linaclotide IR tablets of different strengths is shown in Tables 1 and 2.
-
TABLE 1 Linaclotide IR Tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Isomalt 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Isomalt 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. -
TABLE 2 Linaclotide IR tablets of different strengths Tablet composition (mg/tablet) Components 0.05 0.75 0.15 0.14 0.3 0.6 0.9 Linaclotide 0.05 0.75 0.15 0.14 0.3 0.6 0.9 lsomalt 17 25 50 46.7 100 200 300 Leucine 0.12 0.18 0.36 0.34 0.72 1.44 2.16 Calcium 0.27 0.41 0.82 0.77 1.64 3.28 4.92 chloride PVP K30 LP 0.7 1.1 2.2 2.05 4.4 8.8 13.2 lsomalt 44.7 67.05 134.1 137.5 268.1 536.2 804.3 crospovidone 3.3 5 10 10 20 40 60 Magnesium 0.5 0.75 1.5 1.5 3 6 9 stearate Talc 0.3 0.5 1 1 2 4 6 Total 67 100 200 200 800 1600 2400 - As is illustrated in Table 3, the stability and dissolution performance of the composition illustrated in Table 1 was assessed.
-
TABLE 3 Stability and Dissolution Performance of Linaclotide IR Tablet Dissolution % in (pH 4.5) Linaclotide 15 30 45 Total Condition (mcg/tab) min min min Deg % Initial 133.4 79 98 98 1.96 40° C./75% 135 82 97 98 2.74 RH, 1 month 40° C. 75% 127.8 64 84 85 4.19 RH, 3 months 40° C./75% 124 81 81 81 5.48 RH, 6 months - Linaclotide IR tablets comprising components as shown in Table 4 were prepared in the same manner as described in Example 1. The dissolution and stability performance of the linaclotide IR tablets (0.135 mg/200 mg, HDPE bottle with desiccant) was evaluated at 40° C./75% RH, as is illustrated in Table 5.
-
TABLE 4 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Isomalt 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. -
TABLE 5 Stability and Dissolution Performance of Linaclotide IR tablet Total Dissolution % in (pH 4.5) Linaclotide 15 30 45 Total Condition (mcg/tab) min min min Deg % Initial 140.1 84.6 97 97 2.35 40° C./75% 141.3 93.1 95 95 2.74 RH, 1 month 40° C./75% 136.1 49 85 87 3.54 RH, 3 months - Linaclotide IR tablets comprising components as shown in Table 6 were prepared in the manner described in Example 1. The dissolution and stability of linaclotide IR tablets (0.135 mg/200 mg, HDPE bottle with desiccant) was evaluated at 40° C./75% RH, as is illustrated in Table 7.
-
TABLE 6 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Dicalcium phosphate 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. -
TABLE 7 Stability and Dissolution Performance of Linaclotide IR tablet Total Dissolution % in (pH 4.5) Linaclotide 15 30 45 Total Condition (mcg/tab) min min min Deg % Initial 144.3 78 89 94 2.46 40° C./75, 136 50 81 86 5.53 1 month - Linaclotide IR tablets comprising components as shown in Table 8 were prepared in the manner described in Example 1. The dissolution and stability of linaclotide IR tablets (0.15 mg/200 mg) was evaluated at 40° C./75% RH, as is illustrated in Table 9.
-
TABLE 8 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Microcrystalline cellulose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. -
TABLE 9 Stability and Dissolution Performance of Linaclotide IR tablet Total Desiccant Linaclotide Dissolution % in (pH 4.5) Total Condition (g) (mcg/tab) 15 min 30 min 45 min Deg % Initial N/A 145.4 80 95 94 2.65 40° C./75, 5 132 70 84 85 2.56 1 month 40° C./75, 5 121 73 86 85 8.88 3 months - Linaclotide IR tablets comprising components as shown in Table 10 were prepared in the manner described in Example 1. The dissolution and stability of linaclotide IR tablets (0.15 mg/200 mg) was evaluated at 40° C./75% RH, as is illustrated in Table 11.
-
TABLE 10 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Mannitol 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. -
TABLE 11 Stability and Dissolution Performance of Linaclotide IR tablet Total Desiccant Linaclotide Dissolution % in (pH 4.5) Total Condition g (mcg/tab) 15 min 30 min 45 min Deg % Initial N/A 146.5 84 96 98 1.66 - Linaclotide IR capsules comprising components as shown in Table 12 were prepared using a process similar to that described in Example 1 but without use of the tablet press.
-
TABLE 12 Linaclotide beads (600 mcg/225 mg) % QUANTITY/UNIT COMPONENTS W/W (mg) Linaclotide 0.267 0.600 HPMC (Methocel E5 Premium LV) 0.7 1.575 Calcium Chloride Dihydrate 1.54 3.47 Leucine 0.68 1.54 Microcrystalline Cellulose, NF 96.8 217.8 (Celphere CP305 beads) Hydrochloric acid, NF — — (36.5-38%) Purified water, USP — — TOTAL 100.0 225.0 - The stability and dissolution of the linaclotide IR capsules (35 cap in 45 cc bottle, w/2 g desiccant) were evaluated at 40° C./75% RH, as is illustrated in Table 13.
-
TABLE 13 Stability of linaclotide capsule (150 mcg) Total Dissolution % Capsule Condition Assay Deg % 15 min 30 min 150 mcg, Initial 100.4 1.77 86 94 beads in 40/75, 1 month 97.4 1.77 size 2 40/75, 2 month 97.8 2.79 90 94 gelatin 40/75, 3 month 98 3.46 capsule 40/75, 6 month 92.3 7.98 71 78 - Linaclotide IR tablets comprising components as shown in Table 14 were prepared as described in Example 1.
-
TABLE 14 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.15 0.75 Isomalt 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Isomalt 134.1 670.5 Croscarmellose sodium 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 - The stability and dissolution of the linaclotide IR tablets were evaluated at 40° C./75% RH, as is illustrated in Table 15.
-
TABLE 15 150 mcg tablet, 35 tab in 60 cc bottle, w/5 g desiccant, with croscarmellose sodium as disintegrant Dissolution Assay of Total (normalized) Time Assay* initial % Deg 15’ 30’ 45’ Initial 77.2 100 2.27 100 100 100 40/75, 1 m 74.3 96.2 2.09 40/75, 2 m 78.8 102 2.15 40/75, 3 m 76.8 99.5 1.52 90 90 93 30/65, 3 m 77.3 100.1 1.19 - Linaclotide IR capsules comprising components as shown in Table 16 may be prepared using a process similar to that described in Example 6.
-
TABLE 16 Components Wt. in gms Wt % linaclotide 2.94 0.3 Isomalt 909 90.9 Leucine 22.9 2.29 Calcium chloride dihydrate 25.7 2.57 PVP 40 4 0.0001N HCl 1000* Gelatin capsule 18,000 TOTAL 999.94 100.0 *water is removed during the manufacturing process - Linaclotide IR capsules comprising components as shown in Table 17 may be prepared using a process similar to that described in Example 6.
-
TABLE 17 Components Wt. in gms Wt % linaclotide 8.8 0.3 Isomalt 2805 93.5 Leucine 20.6 0.69 Calcium chloride dihydrate 46.2 1.54 PVP 120 4 0.0001N HCl 1000* Gelatin capsule 18,000 TOTAL 3000.6 100.03 *water is removed during the manufacturing process - Linaclotide IR capsules comprising components as shown in Table 18 may be prepared using a process similar to that described in Example 6.
-
TABLE 18 Components Wt. in gms Wt % linaclotide 2.94 0.3 Mannitol 933 93.3 Leucine 11.5 1.15 Calcium chloride dihydrate 12.9 1.29 PVP 40 4 0.0001N HCl 1000* Gelatin capsule 18,000 TOTAL 1000.34 100.0 *water is removed during the manufacturing process - Linaclotide IR tablets comprising components as shown in Table 19 may be prepared as described in Example 1.
-
TABLE 19 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 PVA 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 20 may be prepared as described in Example 1 using pregelatinized starch as a granular filling agent.
-
TABLE 20 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Pregelatinized starch 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 21 may be prepared as described in Example 1 using trehalose as a granular filling agent.
-
TABLE 21 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Trehalose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 22 may be prepared as described in Example 1 using erythitol as a granular filling agent.
-
TABLE 22 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Erythitol 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 23 may be prepared as described in Example 1 using maltitol as a granular filling agent.
-
TABLE 23 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Maltitol 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 24 may be prepared as described in Example 1 using lactose as a granular filling agent.
-
TABLE 24 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Lactose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 25 may be prepared as described in Example 1 using glucose as a granular filling agent.
-
TABLE 25 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 Glucose 50 250 Leucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 26 may be prepared as described in Example 1 using isoleucine as a stabilizing agent.
-
TABLE 26 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Isoleucine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 27 may be prepared as described in Example 1 using asparagine as a stabilizing agent.
-
TABLE 27 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Asparagine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 28 may be prepared as described in Example 1 using glutamine as a stabilizing agent.
-
TABLE 28 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Glutamine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 29 may be prepared as described in Example 1 using glutamic acid as a stabilizing agent.
-
TABLE 29 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Glutamic acid 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 30 may be prepared as described in Example 1 using histidine as a stabilizing agent.
-
TABLE 30 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Histidine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 31 may be prepared as described in Example 1 using glycine as a stabilizing agent.
-
TABLE 31 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Glycine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 32 may be prepared as described in Example 1 using cysteine as a stabilizing agent.
-
TABLE 32 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Cysteine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 33 may be prepared as described in Example 1 using alanine as a stabilizing agent.
-
TABLE 33 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Alanine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 34 may be prepared as described in Example 1 using serine as a stabilizing agent.
-
TABLE 34 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Serine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 35 may be prepared as described in Example 1 using threonine as a stabilizing agent.
-
TABLE 35 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Threonine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 36 may be prepared as described in Example 1 using tyrosine as a stabilizing agent.
-
TABLE 36 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Tyrosine 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 37 may be prepared as described in Example 1 using proline as a stabilizing agent.
-
TABLE 37 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Proline 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 38 may be prepared as described in Example 1 using tryptophan as a stabilizing agent.
-
TABLE 38 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Tryptophan 0.36 1.8 Calcium chloride dihydrate 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 39 may be prepared as described in Example 1 using KCl as a stabilizing agent.
-
TABLE 39 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Potassium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 40 may be prepared as described in Example 1 using NaCl as a stabilizing agent.
-
TABLE 40 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Sodium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 41 may be prepared as described in Example 1 using MgCl2 as a stabilizing agent.
-
TABLE 41 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Magnesium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 42 may be prepared as described in Example 1 using ZnCl2 as a stabilizing agent.
-
TABLE 42 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Zinc chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 43 may be prepared as described in Example 1 using BaCl2 as a stabilizing agent.
-
TABLE 43 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Barium chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 44 may be prepared as described in Example 1 using MnCl2 as a stabilizing agent.
-
TABLE 44 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Manganese chloride 0.82 4.1 PVP K30 LP 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 45 may be prepared as described in Example 1 using a polaxomer as a stabilizing agent.
-
TABLE 45 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Poloxamer (Pluronic ®) 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 46 may be prepared as described in Example 1 using gelatin as a stabilizing agent.
-
TABLE 46 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Gelatin 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 47 may be prepared as described in Example 1 using chitosan as a stabilizing agent.
-
TABLE 47 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Chitosan 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 48 may be prepared as described in Example 1 using cyclodextran as a stabilizing agent.
-
TABLE 48 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Cyclodextrin 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 49 may be prepared as described in Example 1 using guar gum as a stabilizing agent.
-
TABLE 49 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Guar gum 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 50 may be prepared as described in Example 1 using xanthan gum as a stabilizing agent.
-
TABLE 50 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Xanthan gum 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 51 may be prepared as described in Example 1 using dextran as a stabilizing agent.
-
TABLE 51 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Dextran 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 52 may be prepared as described in Example 1 using dextrin as a stabilizing agent.
-
TABLE 52 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Dextrin 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 53 may be prepared as described in Example 1 using polyethylene polypropylene oxide as a stabilizing agent.
-
TABLE 53 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polyethylene 2.2 11 polypropylene oxide Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 54 may be prepared as described in Example 1 using polyacrylic acid as a stabilizing agent.
-
TABLE 54 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polyacrylic acid 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 55 may be prepared as described in Example 1 using hydroxylpropyl cellulose as a stabilizing agent.
-
TABLE 55 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Hydroxylpropyl cellulose 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 56 may be prepared as described in Example 1 using methyl cellulose as a stabilizing agent.
-
TABLE 56 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Methyl cellulose 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 57 may be prepared as described in Example 1 using hydroxylpropyl methylcellulose as a stabilizing agent.
-
TABLE 57 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Hydroxylpropyl methylcellulose 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 58 may be prepared as described in Example 1 using Poly(sodium vinylsulfonate) as a stabilizing agent.
-
TABLE 58 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Poly(sodium vinylsulfonate) 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 59 may be prepared as described in Example 1 using polyethylene glycol as a stabilizing agent.
-
TABLE 59 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polyethylene glycol 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 60 may be prepared as described in Example 1 using poly(arginine) as a stabilizing agent.
-
TABLE 60 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Poly(arginine) 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 61 may be prepared as described in Example 1 using polycarbophil as a stabilizing agent.
-
TABLE 61 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 Polycarbophil 2.2 11 Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - Linaclotide IR tablets comprising components as shown in Table 62 may be prepared as described in Example 1 using polyvinyl pyrrolidone-co vinyl acetate as a stabilizing agent.
-
TABLE 62 Linaclotide IR tablet, 0.15 mg/200 mg Weight/tablet Theoretical Weight Components (mg) mg/g Linaclotide 0.15 0.75 isomalt 50 250 Leucine 0.36 1.8 Calcium chloride 0.82 4.1 polyvinyl pyrrolidone- 2.2 11 co vinyl acetate Pregelatinized starch 134.1 670.5 Crospovidone 10 50 Magnesium stearate 1.5 7.5 Talc 1 5 0.0001N HCl* — 1100* Total dry weight 200.13 1000.7 *Water is removed during the manufacturing process. - The linaclotide hydrolysis product occurs as a transformation of Asn in the 7 position to Asp (the numbering of linaclotide starts with 1 at the N-terminal Cys). Its structure is depicted below:
- The linaclotide hydrolysis product has been independently synthesized for confirmation of identity using standard solid phase peptide synthesis techniques. The linaclotide hydrolysis product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by recombinant expression of a nucleic acid encoding the linaclotide hydrolysis product (Cys Cys Glu Tyr Cys Cys Asp Pro Ala Cys Thr Gly Cys Tyr, SEQ ID NO: 2), optionally followed by oxidation of the cysteine residues to form the disulfide linkages.
- The formaldehyde imine product occurs as the addition of an imine to the N-terminal Cys (Cys 1) via a formaldehyde-mediated reaction. A proposed structure of the product is depicted below:
- The linaclotide formaldehyde imine product has been independently synthesized for confirmation of identity by reacting linaclotide with formaldehyde (1:5 molar ratio) in absolute ethanol at room temperature for 4 days. The formaldehyde imine product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by chemical peptide synthesis or recombinant expression of a nucleic acid encoding linaclotide followed by formylation as described herein or by other methods known in the art, optionally followed by oxidation of the cysteine residues to form the disulfide linkages.
- The linaclotide oxidation product has a molecular weight of 1542.8. The oxidation product most likely forms as the addition of a single oxygen atom to one of the six cysteinyl sulfurs in linaclotide. One potential structure of the product is depicted below, although one of skill in the art will recognize that the oxygen atom may be attached to any of the other five sulfurs:
- The linaclotide oxidation product has been produced by reacting linaclotide with hydrogen peroxide (3% aqueous) at room temperature or 40° C. for up to 24 hours. The resulting product is enriched in the oxidation product by 1-10%. The linaclotide oxidation product may also be prepared by other methods known in the art, e.g., by isolation from linaclotide preparations using chromatographic techniques or by chemical peptide synthesis or recombinant expression of a nucleic acid encoding linaclotide followed by oxidation of the cysteine residues to form the disulfide linkages followed by reacting linaclotide with hydrogen peroxide or similar oxidizing reagent to form the linaclotide oxidation product.
- Compositions may be prepared which have the molar ratios of stabilizing agent(s) to linaclotide set forth in Table 63.
-
TABLE 63 Molar Ratio of Stabilizers to Linaclotide Molar Molar Molar Molar Molar ratio* 20 ratio 40 ratio 60 ratio 60 ratio 60 Components mg/g mg/g mg/g mg/g mg/g Linaclotide 0.75 0.75 0.75 0.75 0.75 Leucine 1.3 2.6 3.9 5.1 6.4 Calcium chloride dihydrate 1.4 2.9 4.3 5.8 7.2 PVP K30 LP 11 11 11 11 11 Isomalt 253.2 250.4 247.7 245 242.3 Isomalt 670.5 670.5 670.5 670.5 670.5 Crospovidone 50 50 50 50 50 Magnesium stearate 7.5 7.5 7.5 7.5 7.5 Talc 5 5 5 5 5 0.0001N HCl** 1100* 1100* 1100* 1100* 1100* Total dry weight 1000.7 1000.7 1000.7 1000.7 1000.7 *Molar ratio 20 means molar ratio or CaCl2 to linaclotide is 20, and molar ratio of leucine to linaclotide is 20. **Water is removed during the manufacturing process. - Compositions may be prepared which have the molar ratios of filling agent(s) to linaclotide set forth in Table 64.
-
TABLE 64 Linaclotide tablet with different level of tablet filling agent 20% 40% 60% 80% 90% filling filling filling filling filling agent agent agent agent agent Components mg/g mg/g mg/g mg/g mg/g Linaclotide 0.15 0.15 0.15 0.15 0.15 Isomalt 50 50 50 50 50 Leucine 0.36 0.36 0.36 0.36 0.36 Calcium chloride 0.82 0.82 0.82 0.82 0.82 dihydrate PVP K30 LP 2.2 2.2 2.2 2.2 2.2 Isomalt 14.5 38.8 90.1 233.5 700 Crospovidone 3.35 4 5 5.3 22.7 Magnesium 0.5 0.6 0.7 0.8 3.4 stearate Talc 0.3 0.4 0.5 0.5 2.3 0.0001N HCl* — — — — — Total tablet weight 72.2 97.3 149.5 293.1 782 *Water is removed during the manufacturing process. - 1000 g of HCl solution (0.0001N, pH 4) was weighed in a container and polyvinyl pyrrolidone (PVP) (50% of theoretical weight), linaclotide, calcium chloride, and leucine were added into the HCl solution while mixing, until a clear coating solution was obtained. Isomalt and PVP (50% of theoretical weight) were charged into the bowl of the fluid bed (Glatt GCGP 3.0, Glatt, Ramsey N.J.) and mixed for 2 min by fluidizing the powder. The coating solution was top sprayed on the fluidized powder at a speed of 10 g/min and the granules were dried for 20 min at a product temperature of 40° C. The granules were discharged and sieved through a 20 mesh hand screen. The linaclotide granules, isomalt, and croscarmellose sodium were weighed, screened together through a 20 mesh hand screen, charged into a V-blender shell (Patterson-Kelly, East Stroudsburg, Pa.) and mixed for 20 min. Talc was weighed and screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 min. Magnesium stearate was weighed, screened through a 20 mesh hand screen, added to the V-blender and mixed for 3 min. The blend was discharged and added into the hopper of a tablet press. The linaclotide tablets were compressed with a weight of 75 mg and hardness of 4-6 kp. The composition of resulting linaclotide IR tablets of different strengths is shown in Tables 65 and 66.
-
TABLE 65 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Isomalt (powder) 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Croscarmellose sodium 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5.1 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 66 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Isomalt (powder) 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate PVP K30 LP 2 4 14 2 6 12 2 Isomalt (granulated) 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Croscarmellose sodium 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 67 may be prepared as described in Example 60 using pregelatinized starch as a tablet filling agent and crospovidone as the disintegrant. The composition of resulting linaclotide IR tablets of different strengths is shown in 68.
-
TABLE 67 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet) Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Isomalt (powder) 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Pregelatinized starch 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 68 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Isomalt (powder) 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate PVP K30 LP 2 4 14 2 6 12 2 Pregelatinized starch 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 69 may be prepared as described in Example 60 using dicalcium phosphate as a granular tilling agent and crospovidone as the disintegrant. The composition of resulting linaclotide IR tablets of different strengths is shown in 70.
-
TABLE 69 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Dicalcium phosphate 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 70 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Dicalcium phosphate 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate PVP K30 LP 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 71 may be prepared as described in Example 62 using Microcrystalline cellulose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 72.
-
TABLE 71 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Microcrystalline cellulose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 72 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Microcrystalline cellulose 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate PVP K30 LP 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 73 may be prepared as described in Example 62 using Mannitol as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 74.
-
TABLE 73 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 PVP K30 LP 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 74 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate PVP K30 LP 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 75 may be prepared as described in Example 64 using PVA as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 76.
-
TABLE 75 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 76 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 77 may be prepared as described in Example 65 using Trehalose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 78.
-
TABLE 77 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Trehalose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 78 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Trehalose 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 79 may be prepared as described in Example 65 using hydropropyl methyl cellulose as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 80.
-
TABLE 79 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Hydropropyl methyl cellulose 2 26.7 (HPMC) Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 80 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Hydropropyl methyl 2 4 14 2 6 12 2 cellulose (HPMC) Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 81 may be prepared as described in Example 66 using Erythitol as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 82.
-
TABLE 81 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Erythitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 82 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Erythitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 83 may be prepared as described in Example 68 using Maltitol as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 84.
-
TABLE 83 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Maltitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 84 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Maltitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 85 may be prepared as described in Example 69 using lactose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 86.
-
TABLE 85 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Lactose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 86 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Lactose 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 87 may be prepared as described in Example 70 using glucose as a granular filling agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 88.
-
TABLE 87 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Glucose 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 88 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Glucose 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 89 may be prepared as described in Example 65 using isoleucine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 90.
-
TABLE 89 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Isoleucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 90 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Isoleucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 91 may be prepared as described in Example 72 using Asparagine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 92.
-
TABLE 91 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Asparagine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 92 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Asparagine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 93 may be prepared as described in Example 73 using Glutamine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 94.
-
TABLE 93 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Glutamine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 94 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Glutamine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 95 may be prepared as described in Example 74 using glycine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 96.
-
TABLE 95 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Glycine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 96 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Glycine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 97 may be prepared as described in Example 75 using histidine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 98.
-
TABLE 97 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Histidine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 98 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Histidine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 99 may be prepared as described in Example 76 using tyrosine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 100.
-
TABLE 99 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Tyrosine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 100 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Tyrosine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 101 may be prepared as described in Example 77 using lysine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 102.
-
TABLE 101 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Lysine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 102 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Lysine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 103 may be prepared as described in Example 78 using cystine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 104.
-
TABLE 103 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Cystine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 104 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Cystine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 105 may be prepared as described in Example 79 using alanine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 106.
-
TABLE 105 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Alanine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 106 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Alanine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 107 may be prepared as described in Example 80 using serine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 108.
-
TABLE 107 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Serine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Croscarmellose sodium 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 108 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Serine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Croscarmellose sodium 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 109 may be prepared as described in Example 81 using threonine as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 110.
-
TABLE 109 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Threonine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 110 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Threonine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 111 may be prepared as described in Example 82 using proline as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 112.
-
TABLE 111 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Proline 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 112 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Proline 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 113 may be prepared as described in Example 83 using tryptophan as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 114.
-
TABLE 113 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Tryptophan 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 114 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Tryptophan 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 115 may be prepared as described in Example 84 using leucine and potassium chloride as stabilizing agents. The composition of resulting linaclotide IR tablets of different strengths is shown in 116.
-
TABLE 115 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Potassium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 116 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Potassium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 117 may be prepared as described in Example 85 using sodium chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 118.
-
TABLE 117 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Sodium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 118 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Sodium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 119 may be prepared as described in Example 86 using magnesium chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 120.
-
TABLE 119 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Magnesium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 120 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Magnesium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 121 may be prepared as described in Example 87 using iron chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 122.
-
TABLE 121 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Iron chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 122 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Iron chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 123 may be prepared as described in Example 88 using copper chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 124.
-
TABLE 123 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Copper chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 124 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Copper chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 125 may be prepared as described in Example 89 using zinc chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 126.
-
TABLE 125 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Zinc chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 126 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Zinc chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 127 may be prepared as described in Example 90 using aluminum chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 128.
-
TABLE 127 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Aluminum chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 128 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Aluminum chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 129 may be prepared as described in Example 91 using barium chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 130.
-
TABLE 129 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Barium chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 130 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Barium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 131 may be prepared as described in Example 92 using Manganese chloride as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 132.
-
TABLE 131 Linaclotide Table 11 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Manganese chloride 0.003 0.04 Polyvinyl alcohol (PVA) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 132 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Manganese chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 Polyvinyl Alcohol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 133 may be prepared as described in Example 64 using Pluronic as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 134.
-
TABLE 133 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Pluronic 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 134 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Pluronic 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HCl* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 135 may be prepared as described in Example 94 using gelatin as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 136.
-
TABLE 135 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Gelatin 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 136 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Gelatin 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 137 may be prepared as described in Example 95 using chitosan as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 138.
-
TABLE 137 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Chitosan 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 138 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Chitosan 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 139 may be prepared as described in Example 96 using cyclodextrin as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 140.
-
TABLE 139 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Cyclodextrin 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 140 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Cyclodextrin 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 141 may be prepared as described in Example 97 using guar gum as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 142.
-
TABLE 141 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Guar gum 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 142 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Guar gum 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 143 may be prepared as described in Example 98 using Xanthan gum as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 144.
-
TABLE 143 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Xanthan gum 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 144 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Xanthan gum 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1 * — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 145 may be prepared as described in Example 99 using Dextran as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 146.
-
TABLE 145 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Dextran 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 146 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Dextran 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 147 may be prepared as described in Example 100 using Dextrin as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 148.
-
TABLE 147 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Dextrin 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 148 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Dextrin 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 149 may be prepared as described in Example 101 using Polyethylene polypropylene oxide as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 150.
-
TABLE 149 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyethylene 2 26.7 polypropylene oxide Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 150 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyethylene 2 4 14 2 6 12 2 polypropylene oxide Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 151 may be prepared as described in Example 102 using polyacrylic acid as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 152.
-
TABLE 151 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyacrylic acid 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 152 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyacrylic acid 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 153 may be prepared as described in Example 103 using Hydroxypropyl cellulose as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 154.
-
TABLE 153 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Hydroxypropyl cellulose (HPC) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 154 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Hydroxypropyl cellulose 2 4 14 2 6 12 2 (HPC) Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 155 may be prepared as described in Example 104 using methyl cellulose as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 156.
-
TABLE 155 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Methyl cellulose 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 156 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Methyl cellulose 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.000 I N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 157 may be prepared as described in Example 105 using Poly(sodium vinylsulfonate) as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 158.
-
TABLE 157 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Poly(sodium vinylsulfonate) 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 158 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Poly(sodium 2 4 14 2 6 12 2 vinylsulfonate) Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidonc 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 159 may be prepared as described in Example 106 using polyethylene glycol as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 160.
-
TABLE 159 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyethylene glycol 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 160 Linaclotide IR tablets of different strengths Tablet composition of strength (meg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyethylene glycol 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 161 may be prepared as described in Example 107 using Polycarbophil as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 162.
-
TABLE 161 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polycarbophil 2 26.7 Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 162 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate polycarbophil 2 4 14 2 6 12 2 Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - Pediatric linaclotide IR tablets comprising components as shown in Table 163 may be prepared as described in Example 108 using Polyvinyl pyrrolidone-co vinyl acetate as a stabilizing agent. The composition of resulting linaclotide IR tablets of different strengths is shown in 164.
-
TABLE 163 Linaclotide IR tablet, 0.0005 mg/75 mg Weight/tablet Theoretical Weight Ingredients (mg) mg/g Linaclotide 0.0005 0.007 Mannitol 48 640 Leucine 0.001 0.013 Calcium chloride dihydrate 0.003 0.04 Polyvinyl pyrrolidone- 2 26.7 co vinyl acetate Isomalt (granulated) 20.27 270.3 Crospovidone 3.75 50 Magnesium stearate 0.6 7.5 Talc 0.38 5 0.0001N HCl* — — Total dry weight 75 1000 *Water is removed during the manufacturing process -
TABLE 164 Linaclotide IR tablets of different strengths Tablet composition of strength (mcg) 0.5 1 3.5 15 45 90 180 single single 7 day 1 month 3 month 6 month 1 year Components dose dose supply supply supply supply supply linaclotide 0.0005 0.001 0.0035 0.015 0.045 0.09 0.18 Mannitol 48 96 336 48 144 288 46.3 Leucine 0.001 0.002 0.007 0.04 0.12 0.24 0.46 Calcium chloride 0.003 0.006 0.021 0.09 0.27 0.54 1.04 dihydrate Polyvinyl pyrrolidone- 2 4 14 2 6 12 2 covinyl acetate Isomalt 20.27 40.54 141.89 20.27 60.81 121.6 43.75 Crospovidone 3.75 7.5 26.25 3.75 11.25 22.5 5 Magnesium stearate 0.6 1.2 4.2 0.6 1.8 3.6 0.75 Talc 0.38 0.76 2.66 0.38 1.14 2.28 0.5 0.0001N HC1* — — — — — — — Total (mg) 75 150 525 75 225 450 100 - The present invention is not to be limited in scope by the specific embodiments described herein.
- Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims. It is further to be understood that all values are approximate, and are provided for description.
- All patents, patent applications, publications, product descriptions, and protocols are cited throughout this application, the disclosures of which are incorporated herein by reference in their entireties for all purposes.
Claims (31)
1. A pharmaceutical composition comprising linaclotide and a stabilizing amount of a polymer, a stabilizing amount of a sterically hindered primary amine, or a stabilizing amount of a cation, or a combination or mixture thereof.
2. The composition of claim 1 , wherein the composition is a tablet or capsule.
3. The composition of claim 1 , wherein the composition releases at least 80% of the linaclotide within 30 minutes or within 15 minutes of entering a use environment.
4. The composition of claim 1 , wherein the composition releases at least 80% of the linaclotide within 30 minutes or within 15 minutes of entering an agitated buffer solution have a pH of 4.5.
5. The composition of claim 1 , wherein the composition comprises between 0.01 and 10%; between 0.01 and 4%; or between 0.01 and 2% by weight of a polymer, relative to the total weight of the composition.
6. The composition of claim 1 , wherein the polymer is polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), hydroxylpropyl methyl cellulose (HPMC), hydroxylpropyl cellulose (HPC), methyl cellulose, methacrylate polymers, cyclodextrin, dextran, polyacrylic acid, chitosan, guar gum, xanthan gum, polyethylene polypropylene oxide, poly(sodium vinylsulfonate), polyethylene glycol, poly(arginine), poly carbophil, polyvinyl pyrrolidone-co-vinyl acetate, a poloxamer (PLURONIC®), or a combination or mixture thereof.
7. The composition of claim 1 , wherein the composition comprises a molar ratio of sterically hindered primary amine to linaclotide between 100:1 and 1:1; between 100:1 and 30:1; or 60:1 and 30:1.
8. The composition of claim 1 , wherein the sterically hindered primary amine is an amino acid selected from:
a naturally-occurring amino acid selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine;
synthetic amino acid selected from lanthionine, theanine or 1-amino cyclohexane; and
amino sugars selected from chitosan or glucosamine; or
combination or mixtures thereof.
9. The composition of claim 1 , wherein the composition comprises a molar ratio of cation to linaclotide between 100:1 and 1:1; between 100:1 and 40:1; or 100:1 and 60:1.
10. The composition of claim 1 , wherein the cation is calcium, potassium, magnesium, zinc, aluminum, iron, tin, manganese, chromium, cobalt, nickel, barium, sodium, or a combination or mixture thereof.
11. The composition of claim 10 , wherein the cation is a divalent metal cation selected from Ca2+, Mg2+, Mn2+, Zn2+, or a mixture thereof.
12. The composition of claim 1 , wherein the composition comprises a stabilizing amount of a polymer, a stabilizing amount of a sterically hindered primary amine, and stabilizing amount of a cation.
13. The composition of claim 12 , wherein the composition comprises a stabilizing amount of a polymer selected from PVP and PVA, a stabilizing amount of an amino acid selected from leucine, isoleucine, alanine, and methionine, and a stabilizing amount of a cation selected from Ca2+, Mg2+, Zn2+, or a mixture thereof.
14. The composition of claim 13 , wherein the composition comprises (i) between 0.01 and 10 wt. % or between 0.01 and 2 wt. % by weight of a polymer selected from PVP and PVA, (ii) an amino acid selected from leucine, isoleucine, alanine, and methionine in a molar ratio of amino acid to linaclotide between 100:1 and 10:1 or between 100:1 and 30:1, (iii) a cation selected from Ca2+, Mg2+, Zn2+, or a mixture thereof, in a molar ratio of cation to linaclotide between 100:1 and 10:1 or between 100:1 and 60:1.
16. The composition of claim 45, wherein the composition comprises less than 5% by weight; or from 0.05% to 5% by weight; or from 0.05% to 2% by weight of the hydrolysis product.
18. The composition of claim 53, wherein the composition comprises less than 5% by weight; from 0.05% to 5% by weight; from 0.05% to 2% by weight of the oxidation product.
19. The composition of claim 1 , wherein the composition further comprises reduced form linaclotide.
20. The composition of claim 19 , wherein the composition comprises less than 5% by weight; from 0.05% to 5% by weight; or from 0.05% to 2% by weight of the reduced form linaclotide.
21. The composition of claim 1 , wherein the composition further comprises scrambled form linaclotide.
22. The composition of claim 21 , wherein the composition comprises less than 5% by weight; from 0.05% to 5% by weight; or from 0.05% to 2% by weight of the scrambled form linaclotide.
23. The composition of claim 1 , wherein the linaclotide is present in the composition in a concentration of 50 μg to 2 mg.
24. The composition of claim 1 , wherein the linaclotide is present in the composition in a concentration of 75 μg, 150 μg, 300 μg, or 600 μg.
25. A method of treating a gastrointestinal disorder comprising administering to a patient in need thereof, a therapeutically effective amount of the composition of claim 1 .
26. The method of claim 25 , wherein the gastrointestinal disorder is selected from the group consisting of irritable bowel syndrome, constipation-predominant irritable bowel syndrome, dyspepsia (including functional dyspepsia or non-ulcer dyspepsia), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, for example, chronic constipation, opioid induced constipation, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders, combination of symptoms thereof, or combination of irritable bowel syndrome and chronic constipation.
27. A method of treating chronic constipation comprising administering to a patient in need thereof, a therapeutically effective amount of the composition of claim 1 .
28. A method of treating irritable bowel syndrome comprising administering to a patient in need thereof, a therapeutically effective amount of the composition of claim 1 .
29. A method of treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a therapeutically effective amount of the composition of claim 1 .
30. A method of making the composition of claim 1 , comprising:
i) preparing an aqueous solution comprises linaclotide, or a pharmaceutically acceptable salt thereof; and
ii) applying the aqueous solution to a pharmaceutically acceptable carrier.
31. A composition prepared by the method of claim 30 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/840,821 US20130190239A1 (en) | 2009-08-06 | 2013-03-15 | Formulations Comprising Linaclotide |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23172509P | 2009-08-06 | 2009-08-06 | |
US12/851,330 US8748573B2 (en) | 2009-08-06 | 2010-08-05 | Formulations comprising linaclotide |
US13/840,821 US20130190239A1 (en) | 2009-08-06 | 2013-03-15 | Formulations Comprising Linaclotide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/851,330 Continuation US8748573B2 (en) | 2009-08-06 | 2010-08-05 | Formulations comprising linaclotide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130190239A1 true US20130190239A1 (en) | 2013-07-25 |
Family
ID=43544939
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/851,330 Active 2031-06-20 US8748573B2 (en) | 2009-08-06 | 2010-08-05 | Formulations comprising linaclotide |
US13/840,821 Abandoned US20130190239A1 (en) | 2009-08-06 | 2013-03-15 | Formulations Comprising Linaclotide |
US14/286,062 Abandoned US20140287034A1 (en) | 2008-08-15 | 2014-05-23 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
US14/597,599 Abandoned US20150132375A1 (en) | 2008-08-15 | 2015-01-15 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/851,330 Active 2031-06-20 US8748573B2 (en) | 2009-08-06 | 2010-08-05 | Formulations comprising linaclotide |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/286,062 Abandoned US20140287034A1 (en) | 2008-08-15 | 2014-05-23 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
US14/597,599 Abandoned US20150132375A1 (en) | 2008-08-15 | 2015-01-15 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
Country Status (5)
Country | Link |
---|---|
US (4) | US8748573B2 (en) |
JP (2) | JP2013501071A (en) |
CA (1) | CA2770077A1 (en) |
MX (2) | MX2012001660A (en) |
WO (1) | WO2011017502A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120213846A1 (en) * | 2008-08-15 | 2012-08-23 | Forest Laboratories Holdings Limited | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
US8748573B2 (en) | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
US8933030B2 (en) | 2010-02-17 | 2015-01-13 | Ironwwod Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9708371B2 (en) | 2011-08-17 | 2017-07-18 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US10675325B2 (en) | 2010-08-11 | 2020-06-09 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
US11572386B2 (en) * | 2014-09-08 | 2023-02-07 | Auro Peptides Ltd. | Process for the preparation of linaclotide |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140018307A1 (en) * | 2012-07-12 | 2014-01-16 | Forest Laboratories Holdings Ltd. | Linaclotide compositions |
UA119335C2 (en) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Delayed release compositions of linaclotide |
WO2015166468A1 (en) * | 2014-05-02 | 2015-11-05 | Sinoveda Canada, Inc. | Formulas comprising highly soluble elements and vitamin d for the prevention and treatment of bowel conditions during calcium supplementation |
WO2016024291A1 (en) | 2014-08-11 | 2016-02-18 | Sun Pharmaceutical Industries Ltd. | Linaclotide stable composition |
DK3006045T3 (en) | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
WO2016125064A1 (en) * | 2015-02-02 | 2016-08-11 | Aurobindo Pharma Ltd | Stable compositions comprising linaclotide |
EP3302440B1 (en) * | 2015-06-05 | 2021-01-06 | Ironwood Pharmaceuticals, Inc. | Modified or targeted release formulations of linaclotide |
AU2016335287A1 (en) | 2015-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
TWI795462B (en) * | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | Pharmaceutical preparation excellent in light stability and dissolution property |
CN116098864B (en) * | 2023-04-11 | 2023-06-09 | 北京普诺旺康医药科技有限公司 | Linaclotide dry suspension and preparation method thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH658973A5 (en) * | 1983-12-29 | 1986-12-31 | Nestle Sa | FLAVORING PRODUCT. |
JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
JPS63146828A (en) * | 1986-07-18 | 1988-06-18 | Chugai Pharmaceut Co Ltd | Stable granulocyte colony stimulating factor-containing preparation |
DE3729863A1 (en) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | STABILIZED ERYTHROPOIETIN LYOPHILISATES |
JPS649938A (en) | 1987-06-30 | 1989-01-13 | Agency Ind Science Techn | Oral ingestive composition |
JPH03505334A (en) | 1989-04-11 | 1991-11-21 | イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド | Lyophilized peptide formulation |
IT1240314B (en) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES. |
US5221495A (en) * | 1990-04-13 | 1993-06-22 | Colgate-Palmolive Company | Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions |
US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5654278A (en) * | 1994-10-13 | 1997-08-05 | Novo Nordisk A/S | Composition and method comprising growth hormone and leucine |
US5593696A (en) * | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
ZA965368B (en) * | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
BR9710130A (en) | 1996-07-03 | 1999-08-10 | Alza Corp | Non-aqueous protic peptide formulations |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
US6087478A (en) * | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
AU5026599A (en) | 1998-07-23 | 2000-02-14 | Novo Nordisk A/S | A wet granulation method for preparing a stable pharmaceutical formulation |
ID29085A (en) | 1998-11-27 | 2001-07-26 | Kanji Takada | AN ORAL FORMULATION FOR DELIVERY OF GASTROINTESTINAL DRUGS |
US6734162B2 (en) | 2000-01-24 | 2004-05-11 | Minimed Inc. | Mixed buffer system for stabilizing polypeptide formulations |
JP2004501191A (en) * | 2000-06-28 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | Carvedilol |
FR2811884B1 (en) | 2000-07-21 | 2003-01-31 | Oreal | USE IN COSMETICS OF STARCH BETAINATES AND COMPOSITION COMPRISING SAME WITH AT LEAST ONE BENEFICIAL AGENT FOR KERATINIC MATERIALS |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
AU2001296389A1 (en) | 2000-09-29 | 2002-04-08 | Cognetix, Inc. | Stable peptide formulations |
ES2281458T3 (en) | 2000-12-21 | 2007-10-01 | Nektar Therapeutics | STABLE DUST COMPOSITIONS IN INTERLEUCINE RECEIVER STORAGE 4. |
CA2435835A1 (en) | 2001-02-02 | 2002-08-15 | Pharmacia Corporation | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
GB0104371D0 (en) * | 2001-02-22 | 2001-04-11 | Clariant Int Ltd | Color improving stabilizing compositions comprising leucine |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
ES2622468T3 (en) * | 2001-03-29 | 2017-07-06 | Synergy Pharmaceuticals, Inc. | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
AU2002355542A1 (en) | 2001-08-09 | 2003-02-24 | Doctor's Signature Sales And Marketing International Corp. ((Dba)) Life Force International | Protonic formulation |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
IL162618A0 (en) * | 2001-12-21 | 2005-11-20 | Novo Nordisk As | Liquid composition of modified factor vii polypeptides |
JP2003201256A (en) | 2001-12-28 | 2003-07-18 | Hisamitsu Pharmaceut Co Inc | Colic delivery oral pharmaceutical preparation, oral pharmaceutical preparation for treatment of colon cancer and oral pharmaceutical preparation for treating colitis |
DE10261126A1 (en) * | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Storage-stable, liquid fibrinogen formulation |
KR20050088311A (en) | 2002-12-11 | 2005-09-05 | 화이자 프로덕츠 인크. | Controlled-release of an active substance into a high fat environment |
US7304036B2 (en) * | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
SI1594517T1 (en) * | 2003-01-28 | 2007-10-31 | Microbia Inc | Compositions for the treatment of gastrointestinal disorders |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ATE390142T1 (en) * | 2003-05-14 | 2008-04-15 | Indus Biotech Pvt Ltd | SYNERGISTIC COMPOSITION FOR THE TREATMENT OF DIABETES MELLITUS |
BRPI0411114B8 (en) * | 2003-06-10 | 2021-05-25 | Lg Chemical Ltd | stable aqueous solution of human erythropoietin, not containing serum albumin |
CA2529307C (en) | 2003-06-13 | 2013-12-24 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
KR100560697B1 (en) | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | Formulation of albumin-free erythropoietin |
DE202004020676U1 (en) * | 2004-03-10 | 2005-11-10 | Bioceuticals Arzneimittel Ag | Storage-stable liquid erythropoietin formulation, for treatment of renal insufficiency, comprises specified amino acids but no preservatives, urea or albumen and is not a reconstituted lyophilizate |
JP4744533B2 (en) | 2004-12-30 | 2011-08-10 | ドゥビエル カンパニー リミテッド | Spray-dried polymer type collectin protein and method for producing the same |
CA2619650A1 (en) * | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2007044375A2 (en) | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
US7476405B2 (en) * | 2006-02-23 | 2009-01-13 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
EP1996218A4 (en) * | 2006-02-24 | 2012-07-11 | Ironwood Pharmaceuticals Inc | Methods and compositions for the treatment of gastrointestinal disorders |
ITMI20060629A1 (en) * | 2006-03-31 | 2007-10-01 | Daniele Giovannone | ORAL SOLID COMPOSITIONS BASED ON S-ADENOSYLMETIONINE AND PROCESS FOR THEIR ACHIEVEMENT |
WO2008006125A1 (en) | 2006-07-10 | 2008-01-17 | Österreichische Akademie der Wissenschaften | Antimicrobial peptides |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
CA2661521C (en) | 2006-08-31 | 2016-04-12 | Novartis Ag | Pharmaceutical compositions comprising hgh for oral delivery |
JP2010513462A (en) * | 2006-12-20 | 2010-04-30 | バイエル・ヘルスケア・エルエルシー | Factor VII and Factor VIIa compositions |
US8779090B2 (en) | 2007-02-26 | 2014-07-15 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of heart failure and other disorders |
GB0710321D0 (en) * | 2007-05-30 | 2007-07-11 | Nhs Blood & Transplant | Method |
EA020466B1 (en) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP5770629B2 (en) * | 2008-08-15 | 2015-08-26 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Stable solid formulation of GC-C receptor agonist polypeptide suitable for oral administration |
WO2010027404A2 (en) * | 2008-09-04 | 2010-03-11 | Ironwood Pharmaceuticals, Inc. | Stable solid formulation of therapeutic polypeptides suitable for oral administration |
WO2010027405A2 (en) * | 2008-09-04 | 2010-03-11 | Ironwood Pharmaceuticals, Inc. | Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration |
CA2994066A1 (en) * | 2008-12-03 | 2010-06-10 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
CA2770077A1 (en) | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
MX2012001691A (en) * | 2009-08-12 | 2012-02-29 | Forest Lab Holdings Ltd | Orally disintegrating compositions of linaclotide. |
-
2010
- 2010-08-05 CA CA2770077A patent/CA2770077A1/en not_active Abandoned
- 2010-08-05 MX MX2012001660A patent/MX2012001660A/en not_active Application Discontinuation
- 2010-08-05 US US12/851,330 patent/US8748573B2/en active Active
- 2010-08-05 WO PCT/US2010/044522 patent/WO2011017502A2/en active Application Filing
- 2010-08-05 JP JP2012523941A patent/JP2013501071A/en not_active Withdrawn
-
2012
- 2012-02-07 MX MX2019012939A patent/MX2019012939A/en unknown
-
2013
- 2013-03-15 US US13/840,821 patent/US20130190239A1/en not_active Abandoned
-
2014
- 2014-05-23 US US14/286,062 patent/US20140287034A1/en not_active Abandoned
-
2015
- 2015-01-15 US US14/597,599 patent/US20150132375A1/en not_active Abandoned
- 2015-02-12 JP JP2015025192A patent/JP2015098476A/en active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120213846A1 (en) * | 2008-08-15 | 2012-08-23 | Forest Laboratories Holdings Limited | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
US8802628B2 (en) | 2008-08-15 | 2014-08-12 | Ironwood Pharmaceuticals, Inc. | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
US8748573B2 (en) | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
US8933030B2 (en) | 2010-02-17 | 2015-01-13 | Ironwwod Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US10675325B2 (en) | 2010-08-11 | 2020-06-09 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
US10702576B2 (en) | 2010-08-11 | 2020-07-07 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
US9708371B2 (en) | 2011-08-17 | 2017-07-18 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US11572386B2 (en) * | 2014-09-08 | 2023-02-07 | Auro Peptides Ltd. | Process for the preparation of linaclotide |
Also Published As
Publication number | Publication date |
---|---|
US20140287034A1 (en) | 2014-09-25 |
JP2015098476A (en) | 2015-05-28 |
JP2013501071A (en) | 2013-01-10 |
US20110059903A1 (en) | 2011-03-10 |
US20150132375A1 (en) | 2015-05-14 |
CA2770077A1 (en) | 2011-02-10 |
MX2012001660A (en) | 2012-03-26 |
WO2011017502A2 (en) | 2011-02-10 |
US8748573B2 (en) | 2014-06-10 |
MX2019012939A (en) | 2019-12-16 |
WO2011017502A3 (en) | 2011-05-19 |
WO2011017502A9 (en) | 2011-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8748573B2 (en) | Formulations comprising linaclotide | |
US10675325B2 (en) | Stable formulations of linaclotide | |
US20240075094A1 (en) | Low-Dose Stable Formulations of Linaclotide | |
US20150031632A1 (en) | Orally Disintegrating Compositions of Linaclotide | |
US20130012454A1 (en) | Orally Disintegrating Compositions of Linaclotide | |
AU2017379082A1 (en) | Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide | |
US20230173016A1 (en) | Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome | |
US20230142270A1 (en) | Delayed Release Compositions of Linaclotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: FOREST LABORATORIES HOLDINGS LIMITED, BERMUDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEDHIYA, MAHENDRA;MO, YUN;SIGNING DATES FROM 20101012 TO 20101013;REEL/FRAME:030337/0149 Owner name: IRONWOOD PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRETZEN, ANGELIKA;WITOWSKI, STEVEN;GROSSI, ALFREDO;AND OTHERS;SIGNING DATES FROM 20101007 TO 20101020;REEL/FRAME:030337/0324 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |